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As translational research has created opportunity for an increasing number of 
anticancer agents, the need to develop computational methods to identify and 
understand predictive biomarkers has become emergent. This dissertation introduces a 
generic and systematic bioinformatics method to develop biomarker(s) for cancer 
therapeutics. The overall methodology includes the conceptualization of general types 
of biomarkers, implementation of algorithms, a uniqueness test of the signature 
markers in the test data using a novel computational algorithm and innovative 
bioinformatics algorithms to detect the presence of the signature with the pattern 
remained in the test data. An integrated genomic analysis to model gene expression 
and genomic aberrations is proposed to identify the minimal marker sets for clinical 
translation.  
We then study a novel biological phenomenon in cancer therapeutics, that 
cancer cells may show concordant chemo-response to multiple anticancer agents. The 
representative preclinical models (both cell lines and primary tumor derived explants) 
 3 
 
are selected to reflect concordant sensitive and concordant resistant tumor cells. 
Moreover, we developed the gene expression signature of concordant 
chemotherapeutics using NCI60 data to characterize the concordance of 
chemotherapeutics. A high predictive value (AUC = 0.88±0.10) is observed in an 
independent validation using Oncotest tumor clonogenic assay and gene expression 
data from primary xenograft tumor models. When the signature is applied to 
expression data from tumors of breast cancer patients treated with (TFAC) 
combination chemotherapy, the signature predictor predicts treatment outcome (pCR 
vs RD) with a p-value=0.017. We also find that the signature predictor is able to 
predict the survival of patients in breast cancer and lung cancer. Meta-analysis using 
OncomineTM tools shows that more than 20 unique drug sensitivity concepts are 
significantly associated with the developed signature of concordant 
chemotherapeutics. These results demonstrate that concordance of chemotherapeutics 
is present in both preclinical models and clinical patients; the developed signature 
may have clinical utility for patients treated with standard of care chemotherapeutic 
agents in solid tumors.  
In summary, we present innovative bioinformatics methods to develop 
genomic markers for cancer therapeutics and we identify a novel biological problem 
in cancer therapeutics using translational research methods. 
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Chapter 1 Introduction 
1.1 Background 
Cancers are diseases characterized by the uncontrolled growth and spread of 
abnormal cells. According to a World Health Organization report, over 10 million 
cancer cases occur annually, and deaths resulting from cancer worldwide are 
projected to continue rising to an estimated 11 million deaths by the year 2030. 
Although chemotherapy is a well-established therapeutic method for treatment of 
cancers, the clinical pathological response rate to the chemotherapy is usually low due 
to its limited efficacy and adverse effects. Resistance to chemotherapy is the most 
important factor contributing to the low response rate, and it remains a major obstacle 
in the treatment of cancer patients. Chemotherapy resistance occurs when cancers 
cells that have been responding to a therapy -- as evidenced by either growth delay or 
arrest -- begin to grow despite continued treatment. In other words, the cancer cells 
have acquired resistance to the effects of the chemotherapy, and the cancer treatment 
by way of chemotherapy from that point on is ineffective[1, 2]. 
The mechanisms of resistance of chemotherapy are very complex. Some 
cancer cells that are not killed by the chemotherapy may carry gene mutations that 
confer resistance to a drug. Some cancer cells may produce many copies of some 
particular genes, and then trigger an overproduction of protein that may render the 
anticancer drug ineffective. A well known resistance mechanism is when a 
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chemotherapeutic drug is pumped out of the cell by ATP transporter molecules, such 
as p-glycoprotein(ABCB1)[3]. These proteins are able to transport the drugs out of 
the cell, thus preventing drug activity. Some cancer cells may adapt to repair the DNA 
damage caused by some anticancer drugs. As a result, these cancer cells may be able 
to develop a mechanism to make the drugs ineffective[2].  
Although cancer is highly complex and the disease etiologies are still unclear; 
we can now define, and characterize, different types of cancer cells by thousands of 
genetic aberrations, epigenetic changes, post-transcriptional modifications, and 
combinations of these mechanisms, rather than by site of origin using modern biology 
technologies. By unraveling these complexities and decoding cancer pathways, we 
hope to understand why some cancer cells are specifically resistant to a course of 
treatment, and why some cancer cells are highly sensitive to the same treatment. The 
choices of anticancer therapy for individual patients can thus be optimized by 
“translational research” methods. When using the terms “translational science” and 
“translational medicine”; we should define these terms carefully. We define these 
terms as effective translation of the new knowledge, mechanisms, and techniques 
generated in basic science research and clinical research into new applicable 
approaches for prevention, diagnosis, and treatment of disease and to provide better 
healthcare for patients[4, 5]. 
In order to thoroughly understand the cytogenetic and molecular alterations in 
cancer cells, various data types such as large-scale karyotype changes, sequence 
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alterations on protein-coding or regulatory regions, DNA copy number variations, 
epigenetic modification changes, mRNA, protein and microRNA expression are 
needed. Integrative analysis of these data can lead to a comprehensive molecular 
genetics and characterization of cancer cells. Apart from understanding the molecular 
genetics of cancer cells, we are also studying the activities of anticancer drugs in 
different types of cancer cells using comprehensive assays, such as proliferation and 
colony formation assays, which are widely used to screen chemo-response of 
anticancer drugs in both in-vitro and in-vivo models. For example, NCI-DTP 
(National Cancer Institute – Drug Therapeutics Protram) has screened more than 
10,000 anticancer drugs in 60 cell lines using a Sulforhodamine B colorimetric assay, 
and 0 has screened more than 200 anticancer drugs in more than 100 human derived 
explants models using a tumor clonogenic assay[6, 7]. 
Not only do these measurement technologies enable us to observe more about 
cancer cells, but we also now have access to ever-increasing computational power to 
process the vast quantities of information, and assist in the identification and 
characterization the various pieces of the scientific puzzles. The developments here 
point to the need to form hypotheses from all these basic measurements of the cancer 
cells and anticancer drugs at an integrated systems level.  
The work presented in this dissertation is an attempt to address three levels of 
systematic analysis: 1) the development of principled computational methods for 
developing biomarkers and generating hypothesis for cancer therapeutics; 2) the 
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discovery of the association between gene or protein expression and genetic 
aberrations using integrated analysis of different types of complex measurement; and 
3) translation. There are two types of translation: a) translating the generated 
biological hypothesis into a clinical hypothesis and validating it using clinical data; 
and b) translating the learned biology during this process and forming clinical 
hypotheses for validation. 
In this introductory chapter, we will briefly elaborate on some of the points we 
have alluded to above and provide a detailed context for understanding and 
motivating this work. In the later chapters, we will explore the various steps and 
describe how we understand and utilize different types of genomic measurements to 
develop genomic markers for chemotherapeutics, and how we decode complex 
biological data using mathematical and computational methods. 
1.2 Principle of Scientific inquiry 
The process of scientific inquiry is a repeated cycle of observation and 
explanation. When handling biological data, the earliest stages of the cycle sometimes 
consist of pure observation. The first step is to gather the raw material, out of which to 
create questions and then formulate the right questions and seek the answers.  
Today, as we are in the genomic era, overwhelming biological data has been 
and is being generated like a continuing flood. After a period of observation, we may 
naturally begin to ask what kind of biological phenomena exist in the experimental 
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data that, and in some cases, we may notice different biological phenomena from 
what we have learned from textbooks. Followed by observations, critical dry bench 
analysis with mathematical and computational approaches and questions are 
formulated and possible explanations or hypotheses are postulated. Frequently, once 
integrated with multiple biological data, a number of hypotheses that are not 
consistent with the phenomena observed in different data can be rejected 
immediately; however, on the other hand, there may be a number of hypothesis that 
are consistent with the data and should be moved forward to the next stage. The next 
step is to gather more data for further analysis. Usually, we call this “validation”, or at 
a minimum, “hypothesis testing”. If the gathered data for validation is from same 
study, carefully-executed N-fold cross validation will give fairly robust validation 
results. But it is surprisingly easy to mistakenly “peek ahead” in the many steps of 
model building and testing. For that reason, the best standard for validation is when 
the gathered data is taken from another independent study. In the event that the 
hypotheses remain or pass the validation test, more experimentation and observation 
are necessary to distinguish between alternative explanations of the phenomena. In a 
biological study, if the hypothesis is generated from in vitro data, we strongly prefer 
furthering an in-vivo test before translating the hypothesis to the clinic. More on this 
will be discussed in later chapters. For use of predictions in appropriate and ethical 
human clinical studies, not only the in vitro validation, de-novo in-vivo test and 
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de-novo prediction in clinical data must be sound, all the experimental data generated 
and analyzed must also be based on robust statistical theory. 
1.3 Genomic biology 
The structure of DNA was discovered by James Watson and Francis Crick in 
1953. Since that, scientists have started to decode human DNA by developing and 
exploiting an increasing understanding of DNA sequence technology and quickly 
applied this knowledge into drug development. Just as John Sulston thinks “Science is 
essentially a cultural and dynamic activity. It generates pure knowledge about 
ourselves and about the universe we live in, knowledge that continually reshapes our 
thinking”[8], the genomic understanding is the basement of today’s drug 
development. 
A grand milestone of genome research effort was the "Human Genome 
Project". When first proposed, many scientific researchers argued that deciphering the 
human genome would lead to new understanding and benefits for human health. In 
1990, these advocates won over detractors, and the Human Genome Project (HGP) 
was officially launched with funding from the US National Institutes of Health (NIH) 
and Department of Energy (DOE). Labs from all over the world collaborated with the 
NIH and DOE and resolved to sequence 95% of the DNA in human cells. In 2003, 
with heavy involvement from major partners Wellcome Trust (U.K.) and 
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contributions from Japan, France, Germany, China, and other countries, the Human 
Genome Project was successfully completed.  
Today, vast quantities of genomic data are being generated throughout 
genomic biology, including DNA/RNA sequence data, mRNA/miRNA expression 
data, DNA methylation data, DNA copy number variation data and single 
polymorphism data, and protein expression data. The availability of genomic data will 
have a profound impact on biomedical research, diagnosis and therapeutic treatment. 
This also requires scientific researchers to advance systematic computational methods 
to better understand the data. In the following subsections, we will discuss different 
types of genomic data for context.  
1.3.1 Genome sequencing 
The DNA or RNA sequence is the primary structural description of a nucleic 
acid which composes of sequential nucleotides connected by chemical bonds. It can 
be written as a succession of letters representing the nucleotides of a DNA molecule 
or strand. By convention, the primary structure of a DNA or RNA molecule is 
reported from the 5' end to the 3' end. The sequence is considered to have capacity to 
carry information. The DNA genetic sequence carries the inherited information 
content of living functions.  
Sequences can be reported by reading biological raw material through DNA 
sequencing methods. The principle objective of sequencing genomics is to determine 
the sequences of nucleotides that comprise the genomes of various living organisms. 
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In detail, sequencing genomics not only sequences the organism’s chromosomes, it 
also identifies the organism’s genes, introns and exons, proteins coding sequences and 
regulatory elements through genomic analyses. The Human Genome Project has 
completely sequenced the DNA sequence of homo sapiens in 2003. To date, the 
genomes of a large number of other organisms have also been sequenced, including 
panda, yeast, many types of bacteria and dozens of fishes and plants[9].  
In past two decades, the Sanger method of sequencing by capillary 
electrophoresis using the ABI 3730xL(ABI Sanger) platform was widely used as the 
major solution for large-scale sequencing projects, and is recognized as the “gold 
standard” in terms of both read length and sequencing accuracy[10-13]. 
However, the high cost of Sanger sequence based method has greatly limited 
high-throughput sequence data generation. The increasing demand for low-cost 
sequencing is the key driver of the development of high-throughput sequencing 
technologies which dramatically parallelize the sequencing process and are able to 
produce thousands or millions of sequences at once. Several next generation 
sequencing (NGS) technologies have recently emerged, including Roche 454, 
Illumina Genomic Analyzer (GA), and Applied Biosystem (ABI) SOLiD, which are 
able to generate more than three to four orders of magnitude sequence and are 
considerably less expensive than the Sanger method on the ABI Sanger platform. To 
date, these new technologies have been successfully applied towards ChIP-sequencing 
to identify binding sites of DNA-associated proteins, RNA-sequencing to profile the 
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mammalian transcriptome, as well as whole human genome sequencing. Currently 
there is much interest in applying NGS platforms for targeted sequencing of specific 
candidate genes, intervals identified through single nucleotide polymorphism 
(SNP)-based association studies, or the entire human genome in large numbers of 
individuals[14-18]. 
Today, the low cost of high-throughput sequencing technologies is bringing 
the idea of “personalized medicine” closer to reality. The cost of sequencing a single 
whole genome has dropped to within several thousand US dollars. One day, full 
genome sequence data may allow healthcare researchers to investigate an individual’s 
entire genome and therefore detect all disease-related genetic variants, regardless of 
the genetic variant's prevalence or frequency. This will enable the rapidly emerging 
medical fields of “personalized medicine”, and will lead to a revolution in clinical 
genetics. Full genome sequencing is an important step towards better understanding 
the basis of genetic disease. However, it should be recognized that despite 
advancements in genome sequencing technology, incomplete understanding of the 
significance of individual variants or combinations of variants will limit the 
widespread usefulness of full genome sequencing in medicine until its clinical utility 
can be demonstrated [19]. 
1.3.2 DNA copy number variations 
DNA copy number variations (CNV) are alterations of genomic DNA in 
which a certain region of the chromosome has been deleted or amplified. The size of 
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DNA copy number variation ranges from 1 kb to few mb in a single chromosome. 
Copy number variations include deletions, insertions, duplications and more complex 
variants, and have been shown to affect gene expression, phenotypic variation and 
adaptation. The importance of DNA copy number variation in the human genome has 
become increasingly apparent over the last few years. The study of genome-wide 
copy number variation has shown that SNPs will have to share their place in the 
spotlight when it comes to studies of human genetic variation, disease and population 
structure[20, 21]. 
DNA Copy Number Variation(CNV) is caused by genomic rearrangements 
such as deletions, duplications, inversions, and translocations. Segmental Duplications 
(SD) is the typical explanation of genomic rearrangements. Segmental duplications 
are operationally defined as >1 kb stretches of duplicated DNA with high sequence 
identity, for example, Low Copy Repeat (LCR) is a DNA genome region specific 
sequence repeat and is susceptible to result in DNA copy number variations. Any 
change between two copies of DNA sequence, for instance, size, orientation and 
percentage similarity or distance, is susceptible to change in LCR therefore leading to 
genomic rearrangement[22-24]. 
Copy Number Variation(CNV) can be discovered by cytogenetic techniques 
such as fluorescent in situ hybridization, comparative genomic hybridization, array 
comparative genomic hybridization, and by virtual karyotyping with SNP arrays. To 
evaluate gain or loss of specific human samples, Wellcome Trust Sanger Institute 
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researchers have created the human CNV project, which has generated the most 
complete map within the human genome of variation in copy number between healthy 
individuals. To date, the human CNV project has detected CNVs in the genomes of 
270 individuals (the HapMap collection) with mixed ancestry of Europe, Africa and 
East Asia race (http://www.sanger.ac.uk/humgen/ cnv/). 
1.3.3 DNA methylation 
DNA methylation is a type of chemical modification of a DNA sequence. This 
modification can be inherited through cell division and it is subsequently removed 
without changing the original DNA sequence during zygote formation. It is one of the 
several types of epigenetic changes for DNA. DNA methylation typically occurs in 
the context of CpG (cytosine followed by guanine) dinucleotides. Localized regions 
of high CpG frequency (or CpG islands) are located around the promoters of the 
genes that are frequently expressed in cells. Methylated CpG sequence suppresses the 
corresponding genes’ expression. Cytosine methylation is the major form of DNA 
methylation in many mammalians. The methylated cytosine can be converted to 
thymine by accidental deamination, and the methylated CpG sequence will be 
transformed into the TpG sequence, and making the gene inactive[25, 26]. 
There are several assays to discover DNA methylation, such as 
Methylation-Specific PCR (MSP) assay, the HELP assay, and Methylated DNA 
immunoprecipitation (MeDIP) assay. Methylation-Specific PCR assay is based on the 
chemical reaction of sodium bisulfite with DNA that converts unmethylated cytosines 
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of CpG dinucleotides to uracil or UpG, followed by traditional PCR experiment. The 
HELP assay is able to detect and cleave methylated and unmethylated CpG sites using 
restriction enzymes. Methylated DNA immunoprecipitation first isolates methylated 
DNA fragments, and then and puts the DNA fragments into DNA microarrays or 
DNA sequencing (MeDIP-seq)[27, 28]. 
Changes in the pattern of DNA methylation data have been identified 
consistently in cancer cells. In the past decades, DNA methylation was speculated to 
play an important role in the onset or course of cancer. Recently, various changes in 
the DNA methylation patterns or in DNA methyltransferase expression levels in 
cancer cells have been reported. These changes provide a direct and indirect link 
between DNA methylation and cancer cell proliferation. In particular, DNA 
methylation might play a critical role in oncogene and tumor suppress gene 
mutations[29-31]. 
1.3.4 Gene expression 
Gene expression is the phenotypic expression of gene products. It means from 
transcription, through RNA processing to translation and post-translational 
modifications. Alternatively, gene expression refers to the process by which 
information, which is carried by a gene (DNA sequence), is translated to synthesize a 
functional gene product.  
Regulation of gene expression is the very important in the majority of cellular 
activities. It gives the cell control over all structures and functions, such as cellular 
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differentiation, morphogenesis and organism development. Gene expression can be 
modulated, from the DNA-RNA transcription process to post-translational 
modification of a protein. To better understand the regulation of gene expression 
usually requires the exploitation of the genome profiling at DNA, RNA and protein 
levels. In the previous part of this chapter, we have discussed DNA sequencing data – 
gene mutation, DNA copy number variation data – gene copy numbers  and DNA 
methylation data – gene methylation, the combined changes of these factors actively 
lead to the variation of gene expression and functional gene products, which are often 
proteins. In addition, small non-coding RNAs, such as microRNA, and various classes 
of short or long non-coding RNAs may be constantly involved in a variety of gene 
regulatory functions[32, 33]. 
Changes in gene expression underlie many biological phenomena. In cancer 
research, the study of the gene expression, especially the expressions of oncogenes 
and tumor suppress genes, is the critical step. Ideally, gene expression is measured by 
detecting the final gene product, usually the coded protein expression; however it is 
much easier to detect one of the precursors, typically mRNA, to infer levels of gene 
expression, especially in high throughput screening. Therefore, the expression pattern 
of a particular gene or set of genes, such as increases and decreases, measure the 
relative abundance of the gene specific mRNA transcript. In modern molecular 
biology, the high throughput screening of measuring thousands of genes concurrently 
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is called gene expression profiling, and it has been shown to be a powerful tool in 
cancer research[34-42]. 
To date, there are three major technologies have been adopted to profile gene 
expression: DNA microarray technology[43], serial analysis of gene expression 
(SAGE) and RNA-Seq technology[44-46]. Microarrays measure the relative activity 
of previously identified target genes by designing thousands of DNA oligonucleotides 
in the array. However, sequencing based techniques, like SAGE and SuperSAGE, are 
detecting the expression of level of full genomic transcripts instead of predefined set 
genes. Since 2006, the advent of next-generation sequencing techniques has made 
sequence based expression analysis more popular and more accurate when compared 
with microarrays. RNA-seq technology is also called “Whole Transcriptome Shotgun 
Sequencing” method. It is basically using high-throughput sequencing technologies to 
sequence cDNA in order to get information about a sample's RNA content. Till now, 
microarrays are still far more common because of its well validated 
reproducibility[47]. However, RNA-Seq is becoming widely used with reducing cost 
and the technology seems to be more reliable. What is important in this dissertation is 
that microarray technology allows comparison with a vast reference data set of 
published clinical gene expression data generated using the same method. 
In last decade, the technologies of DNA olignucleotide based microarrays 
have advanced tremendously. Both Affymetrix and Illumina have developed arrays 
for different types of scientific research. In a microarray chip, the probes are attached 
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via surface engineering to a solid surface by a covalent bond to a chemical matrix 
such as epoxy-silane, amino-silane, lysine or polyacrylamide. The solid surface is 
usually glass, plastic or a silicon chip. In Affymetrix, the solid surface is the array 
itself, while in Illumina, the solid support is microscopic beads distributed onto the 
array. The quality of DNA microarray data may potentially become problematic due 
to false cross-hybridizations between the design probes and mRNAs[43, 48]. As we 
discussed in our general scientific research methodology, validation is always 
necessary when confirming the basic discovery results. A low-throughput but highly 
validated approach for measuring mRNA abundance is the reverse transcription 
quantitative polymerase chain reaction(RT-PCR), followed with real-time polymerase 
chain reaction (qPCR). RT-PCR generates a DNA template from the mRNA by 
reverse transcription (cDNA). This cDNA template is then used for qPCR, where the 
intensity of fluorescence on the probe changes as the DNA amplification process 
progresses[49].  
1.3.5 MicroRNA expression 
MicroRNAs or miRNAs are short ribonucleic acid molecules, and on average 
they are only 22 nucleotides long. MicroRNAs are usually found in eukaryotic cells. 
MicroRNA is one of the post-transcriptional regulators that bind to complementary 
sequences on target gene mRNA transcripts, and it usually plays a translational 
repressing role that silences gene expression. The human genome has roughly over 
1000 microRNAs and they are predicted or validated to target about 60% of 
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mammalian genes. Some microRNAs are present upon human cell types[50, 51]. 
Some microRNAs have been shown to play either the role of oncogenes or tumor 
suppressing genes. For example, miR-17-5p and miR-20a are shown to mediate E2F1 
pathway activity by transcriptionally repressing E2F1[52, 53].  
Similar to mRNA expression, microRNA expression can be detected using 
microRNA microarrays. MicroRNA is hybridized to microarrays, slides or chips with 
probes to hundreds of microRNA targets, so that relative levels of microRNAs can be 
determined in different samples. More accurately, microRNA expression can be 
quantified with a polymerase chain reaction process of modified RT-PCR followed by 
quantitative real-time PCR. Variations of this method achieve absolute or relative 
quantification. 
1.3.6 Protein expression 
Proteins are the final product of gene expression system. In the cell machinery, 
proteins are the actual workers, and they are synthesized and regulated depending on 
the functional need in the cell. Protein expression refers to the way in which proteins 
are synthesized, modified, and regulated in living organisms. The blueprints for 
proteins are stored in DNA and decoded by highly regulated transcriptional processes 
to produce mRNA, and the mRNA is then translated into a protein. Transcription 
passes the information from DNA to mRNA, and translation is the synthesis of 
protein polypeptides based on a sequence specified by mRNA. After translation, 
protein polypeptides are modified in various ways to complete their structure, 
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designate their location or regulate their activity within the cell. Post-translational 
modifications are various additions or alterations to the chemical structure, and are 
critical features of the overall cell biology. There are a number of post-translational 
modification of proteins in the cell, which include: a) polypeptide folding into a 
globular protein to arrive at the lowest energy state; b) modifications of the amino 
acids; c) disulfide bridge formation or reduction; and d) protein modifications to 
facilitate binding functions, such as glycosylation and acetylation of histone to modify 
DNA-histone interactions[54, 55]. 
During the progression of cancer cells, many signaling proteins are activated 
through genetic, epigenetic and post-translational events[56-60]. The quantitative 
detection of proteins in cells and tissues to discover the expression patterns or changes 
in different conditions, such as health, disease, differentiation and drug treatment, is a 
central aim of proteomics research. The array format is well established for the rapid 
analysis of protein expression. There are three general types of protein arrays: 
large-scale functional chips, analytical capture arrays and lysate arrays. Large-scale 
functional chips immobilize large numbers of purified proteins and are able to assay a 
wide range of biochemical functions, such as protein-protein, protein-DNA, 
protein-small molecule interactions and enzyme activity, and are able to detect 
antibodies and demonstrate their specificity. Analytical capture arrays, also called 
antibody arrays, usually array antibodies, but may also use alternative protein 
scaffolds, peptides or nucleic acid aptamers. They are able to detect and quantify 
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analytes in complex mixtures such as plasma/serum or tissue extracts. Lysate arrays -- 
also called reverse phase proteins arrays – use cell samples, such as tissue lysates, 
printed on an array surface, and the protein targets are then detected with high quality 
antibodies overlaid on them[61, 62]. All three types of assays are widely used in 
diagnostics, clinical biomarkers and discovery research.  
Beside the array techniques, another label-free detection method is mass 
spectrometry. Mass spectrometry sequences the amino acids in a protein and 
compares its amino acid sequence with known proteins. The amino acid sequence also 
can be used to predict the charge of the molecule, its size, and its probable 
three-dimensional structure. The charge and size is confirmed experimentally using 
SDS-PAGE and double-dimension gels. The three-dimensional structure of the 
protein is determined through X-ray crystallography or nuclear magnetic resonance 
spectroscopy (NMR). 
Proteins play a number of different roles within cells, and their interactions are 
the most important biological activities. In this dissertation, we are going to apply our 
developed computational methods for the protein expression data and to develop 
protein expression markers for cancer therapeutics. The integrated analysis with other 
genomic data, such as DNA copy number variation data, DNA methylation data and 
mRNA and miRNA expression, permits us to decode the resistance of 
chemotherapeutics and develop the potential biomarkers for clinical application. 
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1.3.7 Integrated analysis of genomic data 
The first foray into analysis of genomics data are the phenotypic expression 
data, such as gene expression and protein expression. Challenges to the study of gene 
expression and protein expression data are very similar, including data normalization, 
data smoothing, correlating between genes or samples, clustering data, categorizing 
data and using hierarchical clustering methods, principle component analysis or 
singular value decomposition(SVD), or non-negative matrix factorization(NMF) to 
pull out patterns in the data. These enriched analysis methods have successfully 
identified a number of remarkable patterns in the phenotypic expression data[63-65]. 
However, these analyses based on pure phenotypic expression data, such as 
gene expression markers, lack concrete biological explanations of genetic changes, 
such as mutations, copy number variation or methylation, and regulations between 
transcripts or proteins and miRNAs. To better understand the developed phenotypic 
expression markers and apply them in clinical practice, it is necessary to decode the 
over or under expression for specific genes or proteins using the corresponding 
sequence genomics data, copy number variation, methylation data and miRNA data. 
Therefore, we propose a simple mathematical model to describe how genetic 
aberrations change the transcripts expression.  
 )(),(),()( iiii gnMethylatiogCNVgMutationfgExpression   Eq 1-1 
Here )( igExpression  represents the gene or protein expression value of gene i, 
usually it is the normalized readouts from large scale screening array data; 
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)( igMutation  is the mutation of the gene i, especially deletions or frame shift 
mutation; )( igCNV  is the DNA copy number variation value or calls for gene i; 
)( ignMethylatio  is the DNA methylation value for gene i. By using linear 
programming techniques, we can select the meaningful genes whose transcript 
expression is well explained by the corresponding genetic aberrations. However, this 
simple mathematical model does not consider the regional or distant genomic loci that 
regulate the expression of gene i. The gene or protein expression of gene i maybe 
regulated by the approximate location of the gene-of-origin, which is called cis or 
trans regulation. These genomic loci is usually called expression quantitative trait loci 
(eQTLs)[66]. To improve the proposed mathematical model, including the cis and 
trans regulations of the corresponding genomic loci is the direction, however, many 
eQTLs show tissue dependent variation[67], and this may set up a barrier in our 
analysis since we started the biomarker development with the pre-clinical models 
which include multiple cell types. If the biomarker development is focusing on 
specific tumor type, we highly suggest changing the mathematical models as: 
 )(),(),(),()( iiiii gnMethylatiogSNPgCNVgMutationfgExpression   Eq 1-2 
Here, )( igSNP  is the gene i associated SNP’s variation. 
1.4 Chemotherapeutics 
Chemotherapy is a distinct treatment from surgery and radiation therapy in 
treating cancer. Rather than physically removing or destroying a tumor or a part of it, 
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chemotherapy uses anticancer drugs to interact with cancer cells to eradicate or 
control the growth of cancer cells. The anticancer drugs used in chemotherapy are 
able to reach most parts of the body. Therefore, chemotherapy is likely to be 
recommended for cancer that has already spread to other areas of the body, for tumors 
that have occurred at more than one site, or for tumors that cannot be removed 
surgically. It is also used when a patient has the recurrent disease after initial 
treatment with surgery or radiation therapy. 
A single drug may be given or a combination of several different drugs may be 
given together, and this latter approach is called combination chemotherapy. The 
mechanism to kill or stop cancer cells growth is different for different anticancer 
drugs, and combination therapies exploit these differences. Cells divide by going 
through a cell cycle, following an ordered set of events that include the synthesis of 
the DNA (S-phase) and the mitosis (M-phase), when the cell is thereafter divided into 
two daughter cells. Normal cells grow and die in a precise and controlled way, but 
when cancer occurs, the cells growth process becomes abnormal, with cells dividing 
and forming more cells without control and order. In chemotherapy, anticancer drugs 
that interfere primarily with DNA synthesis and mitosis (the S and M phases of the 
cell cycle) are used to destroy cancer cells. Different drugs work through different 
mechanisms: some damage a cell's genetic material (DNA), while others prevent the 
cell from dividing.  
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Typically, there are two types of anticancer drugs: cytotoxic drugs and 
targeted drugs. Chemotherapy with cytotoxic drugs cannot distinguish between 
normal cells and cancer cells other than in gross features of replication; hence both 
types of cells are affected by chemotherapy. The toxicity of chemotherapeutic drugs 
to normal cells is the cause of unwanted side effects. Targeted drugs are intended to 
target the genetic lesions specific to cancer cells and to make cancer cells stop 
accumulating in tumor progression. Targeted drugs thus only target cancer cells and 
are intended to have much less effects on normal cells. Some targeted drugs show 
much better benefits than cytotoxic drugs for certain tumors in clinical use. However, 
the intrinsic value of chemotherapy lies in the fact that the killing effect of 
chemotherapeutic agents has a definite selectivity for cancer cells over normal host 
cells. Normal tissues are able to repair themselves and continue to grow, so the injury 
caused by chemotherapy is rarely permanent.  
In general, cytotoxic agents can be classified into alkylating agents, 
antimetabolites, topoisomerases, vinca alkaloids and taxanes. Alkylating agents are so 
named because of their ability to alkylate many nucleophilic functional groups under 
conditions present in cells. Cisplatin and carboplatin, as well as oxaliplatin, are 
alkylating or alkylating like agents. They impair cell functions by forming covalent 
bonds with the amino, carboxyl, sulfhydryl, and phosphate groups in biologically 
important molecules. Other alkylating agents are mechlorethamine, 
cyclophosphamide, chlorambucil, and ifosfamide. They work by chemically 
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modifying a cell's DNA. Antimetabolites agents include 5-fluorouracil, 
mercaptopurine, trimethoprim, pyrimethamine and pemetrexed. Some of these agents 
replace natural substances as building blocks in DNA molecules, thereby altering the 
function of enzymes required for cell metabolism and protein synthesis. 
Antimetabolites of this sort are cell cycle specific, and are most effective during the 
S-phase of cell division because they primarily act upon cells undergoing synthesis of 
new DNA for formation of new cells. Topoisomerases are essential enzymes that 
maintain the topology of DNA. Inhibition of type I or type II topoisomerases 
interferes with both transcription and replication of DNA by upsetting proper DNA 
supercoiling. Type I topoisomerase inhibitors include Camptothecins: Irinotecan and 
Topotecan. Type II inhibitors include Amsacrine, Etoposide, Etoposide phosphate, 
and Teniposide. Vinca alkaloids such as Vincristine, Vinblastine, Vinorelbine and 
Vindesine, bind to specific sites on tubulin, inhibiting the assembly of tubulin into 
microtubules (M phase of the cell cycle). They are derived from the Madagascar 
periwinkle and Catharanthus roseus. Taxane is the natural product Paclitaxel, 
originally known as Taxol and first derived from the bark of the Pacific Yew tree. 
Docetaxel is a semi-synthetic analogue of Paclitaxel. Taxanes enhance stability of 
microtubules, preventing the separation of chromosomes during anaphase. 
One of the most important decisions for an oncologist is to prescribe the right 
drug with the right amount of anticancer drugs to treat the cancer patients at the right 
time. In this dissertation, one of the main aims is to develop a systematic methodology 
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to identify molecular markers which may help to stratify patients groups for specific 
treatment using anticancer agents. An important phenomenon is that some cancer cells 
show sensitivity to almost all kinds of cytotoxic chemotherapeutic agents. While 
conversely, some cancer cells show resistance to many types of cytotoxic 
chemotherapeutic agents. In this dissertation, we will focus on developing genomic 
markers to elucidate the concordant chemotherapeutics using preclinical materials. 
1.5 Biomarker discovery 
1.5.1 Biomarker for cancer therapeutics 
The development of molecular biological techniques for genetic analysis has 
led to a great increase of our knowledge of genomics in general, and specifically, to 
our understanding of the structure and behavior of cancer genomics. These molecular 
techniques are being used to study biomarkers to stratify cancer patients groups in 
cancer chemotherapeutics, and have been shown great potential to improve the quality 
of patients’ lives. A 70-gene MammaPrint signature (Agendia Inc, Huntington Beach, 
CA) measures the gene expression profile of 70 genes and uses its expression pattern 
to predict the likelihood of distant metastases for early stage breast cancer. This is the 
first molecular marker approved by the US Food and Drug Administration (FDA). 
Another molecular marker, Oncotype DX (Genomic Health), uses its 21 candidate 
genes to estimate likelihood of recurrence. The gene expression signature is composed 
by ER and HER2, as well as ER-regulated genes and several proliferation-related 
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genes. Increasingly, such emerging molecular markers could influence clinical 
care[68-70]. 
Prognostic and predictive efficacy markers are the most important markers to 
guide the selection of the most appropriate chemotherapy for individual cancer 
patients. In the last decades, a lot of retrospective studies on many markers have been 
performed, but only few had been validated in prospective therapeutic trials or 
prospective studies from an accurately selected patient population. The predictive 
efficacy markers or response markers are used to predict the potential “responders” 
for specific chemotherapy or evaluate the probability of “sensitivity/response” for the 
individual patient to the chemotherapy. Prognostic markers, such as Agendia’s 
MammaPrint signature and Genomic Health’s Oncotype DX signature, are used to 
estimate the likely outcome of treatment, for instance, the recurrence of tumor growth 
after primary treatment for the cancer patients. Prognostic markers play a key role in 
clinical practice in distinguishing patients into different risk groups and providing 
guidance for doctors to design treatment strategies in the care for patients. For 
example, the amplification of MYCN proto oncogene is a known indicator of poor 
outcome in neuroblastoma patients, therefore, patients with MYCN amplication need 
more challenging clinical care[71]. 
Typically, there are two types of biomarkers in clinical applications: 
prognostic markers and efficacy markers. Prognostic markers may be generic and can 
predict the response of multiple chemotherapies; while efficacy markers may be 
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specific and it can only predict one or a combination of anticancer agent(s). Although 
prognostic biomarkers that provide information on the natural course of disease after 
standard treatments are useful, predictive biomarkers are of greater value in clinical 
decision making and will be essential tools to provide the tailoring treatments for 
cancer patietns. The measurement of efficacy of anticancer agents in solid tumors is 
based on pathological response using the RECIST criteria, categorized as complete 
pathological response, partial pathological response, stable disease or progression. 
The measurement of general prognosis, however, is based on patients’ survival, such 
as progression free survival, disease free survival and overall survival. Patient 
survival is highly correlated with the patient’s chemotherapeutic response to 
anticancer agent(s), if chemotherapy was chosen as the primary care for a cancer 
patient. The aim of our research is to develop molecular markers to stratify cancer 
patients for standard of care chemotherapies. In this dissertation, we will not 
specifically discuss whether the developed markers have prognostic value, or if they 
are purely efficacy markers. 
Tumor response to chemotherapy varies from one patient to another. It would 
be extremely useful to know ahead of time whether tumor cells of an individual 
patient would respond to chemotherapeutic agents, or whether an individual patient 
would show resistance to the chemotherapy. There are three types of molecular 
markers that provide guidance for chemotherapy treatment on clinical practice: a) the 
targeted genes; b) the activity of the targeted pathways; c) the genes are indirectly 
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related with the agent’s or targeted pathway. The drug targets are the most important 
markers for the targeted anticancer agent. The clinical response rate of Gleevec is 
highly dependent on the targeted genes, mutation of BCR-ABL gene and over 
expression of C-KIT. Patients with HER2 amplification show 20% higher response 
rate than patients with HER2 normal copy number to the Herceptin[72, 73]. The 
activity of the targeted pathway is also the key marker for the drug’s clinical response. 
For example, a patient with K-Ras mutation may show much worse response than a 
patient with wild type K-Ras to Panitumumab, which is a fully human monoclonal 
antibody specific to the epidermal growth factor receptor (EGFR). This is because a 
patient with a K-Ras mutation will lead to constitutively active downstream signaling 
of the pathway unaffected by the drug target[74, 75]. Apart from drug targeted genes 
and targeted pathways, there are also some molecular markers which are not directly 
related with the targeted pathways for example, ABCB1, TOP2A, ERBB2, and BCL2 
are candidates of predictive markers to predict the chemosensitivity for cytotoxic 
chemotherapy in breast cancer[76]. 
1.5.2 Biomarker development for cancer therapeutics 
The current primary focus of the translational research is to improve clinical 
outcomes by utilizing clinical validated biomarkers. According to the guidance from 
FDA pharmacogenomics, biomarkers are classified into three types: a) exploratory 
marker; b) probable validated marker and c) validated marker (FDA report 2004). An 
exploratory marker is more like a clinical hypothesis, for example, Taxane shows 
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resistance in the patients with β-tubulin mutations. A probable validated marker 
means that marker has been validated by some biological or clinical data, for example, 
Taxane shows higher IC50 in cell lines with β-tubulin mutations than cell lines 
without β-tubulin mutations. A validated marker means that a probable validated 
marker is confirmed in clinical trials, and has shown usefulness in improving clinical 
outcomes.  
Remarkable advances in the understanding of neoplastic progression at the 
cellular and molecular levels have spurred interest in molecularly targeted cancer 
therapeutics. New imaging and bioassay technologies are providing the basis for 
developing biomarkers that will facilitate development of these molecularly targeted 
drugs. Biomarkers may be used in early drug development to elucidate the mechanism 
of action of a drug and provide preliminary evidence of its effect. As the relationship 
between a drug or class of drugs and a biomarker becomes better understood, there is 
a hope that clinical assays can be developed to identify patients most likely to benefit 
from the drug. These biomarkers are termed predictive biomarkers. Although 
prognostic biomarkers that provide information on the natural course of disease after 
standard treatments are useful, predictive biomarkers are of greater value in clinical 
decision making and will be essential tools for tailoring treatments. 
NCI, FDA and drug makers have consensus about the facing challenges in 
drug and biomarker co-development in an seminar discussion[77]. The critical issue 
to develop both drug and corresponding biomarkers are highly depended on the level 
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of understanding of the biology of the drug target and its interaction with the drug. 
This means to understand the underlying biology of the drug target and the 
mechanism of action of the drug is the still the key to speed up the process of drug 
and biomarker co-development. Therefore, the pre-clinical models are the good 
starting point for the biomarker development, especially to study the biology of the 
drug target and the mechanism of action of the drug, and to discover the probable 
marker and to develop and to evaluate biomarker assay performance. 
In the recent few years, remarkable advances in the understanding of 
cancerous progression at the cellular and molecular levels have spurred interest in 
oncogene or oncogene like addicted molecular targeted therapeutics. The latest news 
is the approvement of Zelboraf by FDA[78]. Zelboraf, which is specifically inhibiting 
mutated B-Raf protein, offers significant survival benefit in metastatic melanoma 
patients. The BRAF protein is involved in cell signaling pathway and promotes cell 
proliferation if over active. It is mutated in 50 percent of late-stage melanoma patients. 
Since Zelboraf selectively inhibits the mutated BRAF V600 protein, therefore, 
patients with B-Raf V600 mutation will likely show response to Zelboraf. Roche also 
developed Cobas 4800 BRAF V600 mutation assay to test the mutation in clinical 
patients. However, other than Zelboraf, there are many other targeted drugs are not 
“lucky” to have 50 percent of mutations for their drug targets in patients, and the 
tumor cells in patients may not show apparent tumor growth addiction on the drug 
targets as well. Therefore, the development of biomarkers for these drugs is also very 
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challenging, especially the number of available pre-clinical models is limited. What is 
needed here is the sophisticated methodology to identify the potential markers based 
on small size pre-clinical samples. Advanced bioinformatics analysis with new 
genomic and bioassay technologies are providing the basis for developing biomarkers 
that will facilitate development of these molecularly targeted drugs. In this 
dissertation, we will try to propose a systematic methodology to develop probably 
validated biomarkers for anticancer agents using a model driven analysis of genomic 
data and chemo-sensitivity data. Although there are some pioneer bioinformatics 
works done in the past decade [70, 79] [80], there is no systematic procedure to 
develop the probable validated markers for most standard of care chemotherapeutics 
and targeted agents.  
Data driven analysis methodologies have been useful in uncovering interesting 
patterns to form exploratory hypothesis in the biological and clinical data. We use the 
following framework to integrate genomic data and chemo-response data in order to 
develop and validate biomarkers for cancer therapeutics. 
The developed probable markers may be used in early drug development or 
for further academic research to elucidate the mechanism of action of a drug and 
provide preliminary evidence of its effect. As the relationship between a drug or class 
of drugs and the marker becomes better understood, there is hope that clinical assays 
can be developed and move to clinical for further validation and to identify patients 
most likely to benefit from the drug.  


















Figure 1-1: Framework to develop an exploratory marker, a probable validated 
marker and a validated marker for anticancer agents. 
1.6 Combination chemotherapy 
Combination chemotherapy is the use of more than one drug or therapy for 
cancer treatment in a patient. For some cancers, the best treatment strategy is a 
combination of surgery, radiation therapy, and chemotherapy. Sometimes 
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combination chemotherapy is used. Anticancer agents like cytotoxic drugs that are 
used to treat different cancers have variable outcomes. For example, only about 20% 
of patients with breast cancer respond therapeutically to the widely used drug Taxane 
(Paclitaxel or Docetaxel). Chemotherapy agents, especially cytotoxic drugs, often 
cause unwanted side-effects. Cytotoxic drugs work by killing cells which are 
dividing, and so some normal cells are consequently damaged too. Since the response 
rate is low and toxicity is high, combinations of a cytotoxic drug and other 
chemotherapeutic agents have been developed. The rationale for combination 
chemotherapy is to use drugs that work by different mechanisms of action, thereby 
decreasing the likelihood of developing resistant cancer cells. When drugs with 
different effects are combined, each drug can be used at its optimal dose without 
intolerable side effects. There are three types of measureable effects in combinational 
chemotherapy: synergistic, antagonistic and additive. If the combined agents show 
beneficial effect(s) to each combined agent, the combinational effect is considered 
“synergistic”; if the combined agents do not show favorable effects to one other, the 
combinational effect is considered “antagonistic”; and if the combined agents show 
similar effects as individual drugs, the combinational effect is considered “additive”. 
Mathematically, this is often evaluated by the use of a “Combination Index (CI)”[81]. 
In another situation, even the synergistic drug combination is identified, the toxicity 
of the drug combination will also need to be investigated. Usually, the combined 
drugs are treated to the patients sequentially to avoid the accumulation of the toxicity. 
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The success of many targeted cancer therapies are based on their efficacy only 
when they are combined with cytotoxic agents in chemotherapeutics. For example, 
bevacizumab did not show any survival benefit as a monotherapy for patients with 
metastatic colorectal cancer, but it gave extra 2.5-month survival advantage when 
used in combination with the FOLFOX4 (Oxaliplatin, Leucovorin and Fluorouracil) 
chemotherapy regimen[82]. These success stories of the combination of targeted 
drugs with cytotoxic agents based chemotherapy has led to the hypothesis that 
efficacy of traditional chemotherapies could be enhanced by incorporating with 
targeted agents. However the mechanisms of such combinations are still unclear. It 
would be very helpful to provide scientifically based rationales for drug combinations 
between targeted agents and cytotoxic agents. We hope to extend the computational 
framework of the evaluation of single agent biomarkers into the evaluation of 
combinations of biomarkers. With the focus on optimizing dose regimens and 
understanding of developed biomarkers, it is possible to stratify patients into 
subpopulations who could benefit from such combinations. 
1.7 Dissertation roadmap 
In this dissertation, we will first propose a computational framework to study 
biomarkers to guide cancer chemotherapeutics. In particular, we will present the 
bioinformatics method to generate the principal markers based on gene or protein 
expression data and anticancer agents’ in vitro chemo-response data. Next, we suggest 
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a novel computational method to test the uniqueness of the developed marker genes in 
the test data. Finally, we will further provide a robust method to detect the presence of 
the developed signature marker in the test data. By integrating mutation data, copy 
number variation data and methylation data, we can identify genes which are 
biologically meaningful and present strategies to narrow down the multiple gene 
signature into N(N<10) number of marker set for clinical translation. Another major 
part of the dissertation is to use translational research method to study novel 
biological problem in cancer therapeutics. 
Overall, there are three major objectives for this work: 
1. to develop a systematic bioinformatics methodology for studying 
molecular markers for cancer chemotherapeutics, and 
2. to propose minimal marker set for clinical validation and practice, and 
3. to study novel biology by using translational research methods 
The outline of the dissertation is as follows: In this chapter, the backgrounds of 
genomic biology, cancer chemotherapeutics, biomarkers and their application to 
improve chemotherapeutics are introduced. In Chapter 2, bioinformatics methods to 
develop principal markers based on principle expression data will be presented and the 
methods to test the robustness of the developed expression marker and to detect of the 
presence of expression marker in test dataset will be proposed. In Chapter 3, a method 
to integrate different types of complex genomics data, such gene expression, mutation, 
copy number variation and method methylation data and develop robust single marker 
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will be presented and strategies to propose minimal marker set to clinical validation 
will be discussed. In Chapter 4, a novel biological problem, concordant 
chemotherapeutics will be identified, and the corresponding molecular markers will be 
generated to characterize the concordant response among chemotherapeutics. The 
developed genomic signature is then validated in both in vitro data and clinical data. In 
the last chapter, we will summarize our study and contributions to the field. 
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Chapter 2 A systematic bioinformatics 
methodology to develop principal markers  
Gene expression and protein expression are the phenotypic expression of gene 
products. Ideally, a group of genes or proteins with a combined expression pattern 
could uniquely characterize the condition of phenotype of biological species, such as 
disease state of cancer patients and chemo-response of anticancer agents. Therefore, 
gene or protein expression signature can serve as a principle surrogate marker for the 
studies of molecular phenotype, pathology, prognosis and diagnosis of cancers. For 
example, gene expression profiling using microarrays has been successfully applied 
for the classification of tumor types, stages of tumor progression, prediction of 
clinical outcomes and prediction of the response of anticancer agents[83-98].  
The biological implication of the gene expression signatures is intrinsic, and 
the biological connection between genes identified by microarray and their 
phenotypic effect usually remains elusive. A signature gene set contains some false 
positives by nature of high throughput. Current advances in controlling the false 
discovery rate have overcome this problem to some extent, solidifying the status of 
expression profiling as the gold standard among non-biased genome wide approaches. 
In this chapter, we will review a few key technologies adopted to develop principle 
markers based on gene or protein expression arrays. The focus on of this chapter is to 
develop an innovative systematic methodology to discover biomarkers. 




In the last 10 years, microarray technology has been greatly advanced and has 
substantially gone from obscurity to being almost ubiquitous among biologists. 
Biologists today run high-throughput genomic studies by simultaneously measuring 
the expression levels of tens of thousands of genes in their biomedical research. One 
of the major applications is to use microarrays to discover differentially expressed 
genes between two or more groups, such as normal versus cancer patients, responders 
versus non-responder, control versus and drug treated. These identified differentially 
expressed genes may represent disease biomarkers in the diagnosis of the different 
types and subtypes of diseases or in the efficacy markers of anticancer agents in 
chemotherapy. The objective of principle marker development is to identify genes or 
proteins which show statistically significant up-and-down expression patterns in two 
groups of samples (Figure 2-1). In microarray derived gene expression parlance, it is 





















Group 1         Group 2 
Figure 2-1: Schematic data matrix of the principle expression signature 
The most straight forward approach to identify differentially expressed genes 
is known as the “fold-change” (FC) and it is calculated as 
21 uuFC   Eq 2-1 
Where,  and  are typically the means of log-transformed gene expression in 
group 1 and group 2. 
The FC method simply evaluates the average log-ratio between two groups, 
and considers the gene differentially expressed if the log-ratio difference is greater 
than a specified cut-off. The FC method represents the “up” and “down”, or “high” 
and “low”, or “over” and “under”, or “on” and “off” of the gene’s expression. This is 
the preliminary criteria for a gene to be a biomarker in clinical. However, the FC 
method lacks solid statistical footing because it assumes that the variance of the gene 
expression in two groups is equivalent. This assumption is especially problematic 
since variability in gene expression measurements is not uniform, even after the 
High Low 
Low High 
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variance has been stabilized by data transformation. Statistically, using this FC 
method alone with a fixed cutoff gives undetermined type 1 error rates. 
Rather than applying a FC cutoff alone, a statistical test that incorporates 
variances of gene expression should be preferred. The student t-test is certainly the 
most popular test and has been considered as the fundamental method for differential 
gene analysis, especially for testing significant changes in small samples. The null 



















2S are the unbiased estimator of the variance of the expressions of the gene in 
group 1 samples and group 2 samples[99]. 
Another well known t-test based method is the Significance Analysis for 
Microarrays (SAM)[100, 101]. Estimating t-statistic could be problematic because the 
standardized variance can be skewed by low variation genes, which are false positives 






Where, S  denotes the pooled standard deviation of both group samples, and OS  is 
a small constant for stabilizing the standard deviation. 
The statistical power of t-test statistics is usually small when the sample size is 
small. Baldi and Long[102, 103] highlighted this problem by way of showing how 
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estimates of sample variances are poor when the sample size is small. Consequently, 
they introduced a Bayesian framework to evaluate the variance to perform standard 












Where, 20 is denoted as a background variance, 0w is defined as the weighted 
parameter and 2s is the empirical sample variance. The weighted parameter 0w is 
interpreted as a measure of confidence in the Bayesian estimate of the variance in 
comparison to the sample variance. The overall method is named as Cyber-T method. 
Another variance modeling method has been proposed by Delmar and his 
colleagues[104]. The mixtures of distributions are employed to improve the estimate 
of the variance. The variance 2 is modeled as a weighted mixture of Gamma 
distributions, and the parameters of the mixture model are estimated from the 
observed data by expectation maximization (EM) approach. 
Smyth[105] presented a different method that was based on general linear 
models, and named it as Limma. Limma is not restricted for two classes comparisons 
because it basically use the generalized linear model to fit the expression data for each 
gene 
bxay   Eq 2-5 
Where, y denotes the gene expression data, the log-transformed normalized gene 
expression array data, and x  represents the experiment design matrix or phenotype 
data, such as treatment and control, while b is the intercept vector. The subsequent 
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analysis is based on the fitted model parameters. Limma can not only identify 
significantly differential genes between two groups of samples, but can also be used 
for the analysis of more groups, factorial designs and time course experiments. 
The statistical significance of the differential expression analyzed by testing 
each gene, multiple hypothesis testing is then an immediate concern. When multiple 
hypotheses are tested, the probability that a type I error is dedicated increases sharply 
with the number of hypotheses. Considering that thousands of genes can be analyzed 
in a single experiment, this may dramatically intensify the problem. (While 
controlling the family-wise type I error rate (FWE), which is the probability of one 
error in the family of hypotheses is needed. Benjamini and Hochberg[106] pointed out 
that the estimate proportion of the errors among the identified differentially expressed 
genes may be more appropriate. They proposed a concept “false discovery rate 
(FDR)” which is actually the expectation of FWE of the identified significantly 
differentially expressed genes. FDR criterion in the simultaneous testing of gene 
expression has been shown to be more powerful procedures[107-109]. 
All the above procedures of differential gene expression analysis can be used 
to analyze protein array data. Our ultimate goal in developing gene or protein 
expression markers is to translate these microarrays or protein arrays profiles into 
clinical practice and use them to guide the treatment of cancer patients or stratify 
patients for specific chemotherapeutics. In clinical practice, chemotherapeutics used 
against cancer may get a range of responses, such as complete response, partial 
response, stable disease response and progression disease response. Therefore, we 
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cannot restrict our study of differentiation markers analysis to one or two class 
samples. Hence, we will need to extend the analysis from two classes to three classes 
and more. 
2.2 Fuzzy classification of biological data 
Biological data is inherently uncertain and noisy; when handling uncertain 
biological data, it is difficult to separate measurement errors from inherent variability. 
A Boolean Network (BN) model, which simply considers gene expression as “on” or 
“off”, has been used to model gene regulatory networks and discover the gene 
expression patterns[110-114]. In the Boolean network formalism, a gene is considered 
to be either expressed or unexpressed, so intermediate expression levels are neglected. 
In reality, a gene can be expressed at intermediate levels, and to model these cases we 
need an alternative model to cover them. A “Fuzzy” clustering method can deal with 
such situations[115, 116]. A Fuzzy approach provides a systematic and unbiased way 
to imitate human intelligence by using qualitative descriptors such as “high” or “hot” 
to reduce the complexity of the natural characteristics of the data. In this study, we 
cluster the chemo-response data, such as GI50s and IC50s, into three fuzzy classes: 
“sensitive”, “medium” and “resistant”. The clustering method uses formal data 
discretization algorithms. For example, Figure 2-2 describes the classification of 
NCI60 cell lines based on the chemo-response data NLogGI50 (Negative 
log-transformed GI50) of Paclitaxel. 52 solid tumor cell lines are classified into three 
fuzzy clusters (sensitive, medium and resistant) using fuzzy c-means (FCM) method 
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with the three centers: Sensitive is 8.5; Medium is 7.5 and Resistant is 6.5. Samples 
with NLogGI50 greater than 8 are classified as “sensitive”; samples with NLogGI50 
less than 7 are classified as “resistant”; and samples with NLogGI50 between 7 and 8 




Figure 2-2: Classification of 52 NCI60 solid tumor cell lines based on NLogGI50 
readouts of Paclitaxel. 
2.3 Signature markers development 
 Fuzzy classification methods may cluster samples into three or more than 
three classes, such as “low”, “medium” and “high” for gene or protein expression; and 
“sensitive”, “medium” and “resistant” for chemo-response data. The statistical 
methods to develop significantly differentiated signature markers between two classes, 
such as “sensitive” and “resistant” samples, are state-of-the-art and have been well 
studied, but few methods have been presented to develop signature markers for three 
or more classes. Therefore, in this dissertation, one of the major tasks is to propose a 
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computational methodology that develops principal genomic markers, including the 
development of signature markers for samples with three or more classes. 
Since this study is focused on developing biomarkers for chemotherapeutic 
agents, we have chosen to develop chemo-response signature markers for a start. 
Figure 2-3 depicts the typical expression pattern of signature markers developed 
based on two classes samples: markers(sensitive) show high expression in sensitive 
samples but low expression in resistant samples; markers(resistant) show low 
expression in sensitive samples but high expression in resistant samples. Many 
methods reviewed above, like SAM and Limma procedures, are very powerful in 
developing significantly differentially expressed markers. Table 2-1 lists the 
implementation of R scripts using Limma procedure to identify the top 300 
significantly differentially expressed gene markers in microarray data. This 
implementation also includes the pre-processing steps of microarray data genes that 
expressed background level expression and do not vary significantly across all 
samples are excluded in the study. The R packages utilized in the following R scripts 
are “Limma”(version 3.6.9) and “genefilter”(version 1.32). 




Table 2-1: R scripts using Limma procedure to identify the most significantly 
differentiated genes between two class samples 
However, this Table 2-1 only identifies the gene markers that have just two 
levels of expression: high and low in this pattern. When we extend the current two 
classes to three classes by considering “medium” samples, we obtain two types of 
expression patterns: type-I and type-II. In type-I, the expression of the marker has 
three categorical levels: high, medium and low. As shown in Figure 2-4, both 
markers(sensitive) and markers(resistant) keep the same pattern in both sensitive and 
resistant samples, but they show “medium” expression in the newly added “medium” 
samples. In type-II, the expression of the marker has two levels: high and low, 
therefore, a new group of markers, markers(medium), is identified to show high 
expression in medium samples and low expression in both sensitive and resistant 
samples (Figure 2-5). In this case, each class samples, either sensitive, medium or 
// ExprArray: microarray expression data, matrix format 
// ResponseClass: response class information, numeric vector 
library(genefilter) 
## filter out the probesets with noisy level expression 
f1 = pOverA(0.25, log2(100)) 
## filter out the probesets with insignificant variation expression 
f2 = function(x) (IQR(x) > 0.5) 
Fun.Filter = filterfun(f1, f2) 
selected = genefilter(ExprArray, Fun.Filter) 
ExprArray.PreProcessed = ExprArray[selected, ] 
library(Limma) 
design = cbind(mean = 1, diff = as.numeric(ResponseClass)) 
fit  = lmFit(ExprArray.PreProcessed, design) 
fit2 = eBayes(fit) 
topGenes = topTable(fit2,coef="diff",number=300,adjust.method="BH", sort.by="logFC") 
Expr.SigDiff  = ExprArray.PreProcessed[topGenes$ID,] 
Feature.Expr = cbind(topGenes[,c("logFC","adj.P.Val")], Expr.SigDiff) 
rownames(Feature.Expr) =  topGenes[,"ID"] 
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resistant, have the corresponding representative markers, which are named as 
“markers(class name)”. These markers only show “high” or “active” expression in 
these class samples, but show “low” or “silent” expression in all other classes samples. 
Therefore, the generalized expression patterns of the signature markers for “N 
classes” is defined as: a) type-I markers’ expression is significantly correlated with 
the rank of chemo-response data; b) type-II markers is the combination of over 
expression markers or under expression markers which are only significantly “over” 
or “under” expressed in the specific class i (i=1, 2, …, N) samples but significantly 
“under” or “over” expressed in all other classes (1, 2, i-1, i+1, …, N) samples. For our 
interests, we have focused on the over expression markers. 
Sensitive          Resistant 
Figure 2-3: The expression pattern of the chemo-response signature markers for 
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Sensitive      Medium       Resistant 
Figure 2-4: The expression pattern of type-I chemo-response makers for three 
classes: sensitive, medium and resistant samples 
 
Sensitive      Medium      Resistant 
Figure 2-5: The expression pattern of type-II chemo-response (over expression) 
markers for three classes: sensitive, medium and resistant samples 
Our next task is to build up a mathematical algorithm and implement it to 
extract both type-I and type-II signature markers for “N class” samples. The 
Low Medium High 
High Medium Low 
High Low Low 
Low High Low 
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expression of the type-I markers are significantly correlated, either positively or 
negatively, with the rank of response class(from 1 to N). Hence, we can use the 
correlation analysis method to develop type-I markers. Pearson product-moment 
correlation coefficient (denoted by r here) is a measure of the correlation or linear 
dependence between two variables (Eq 2-6). Another statistic metric to measure 
correlation is Spearman’s rank correlation coefficient (denoted by ρ here), which is a 
non-parametric measure of statistical dependence between two variables. It estimates 
the monotonic trends of two variables. The Spearman correlation coefficient is 
defined as the Pearson moment correlation coefficient between the ranked variables. 
We employ the correlation coefficient method to measure the correlation between the 
expression of each marker and the rank of response class. In the meanwhile, the fold 
change method is used as the preliminary criteria to ensure that the expression of the 
signature marker between two adjacent class samples, such as class j samples and 
class j+1 samples, is significantly different. After calculating the correlation 
coefficient, we performed the statistical test to select the markers which show 
significant correlation with the rank of response class. Thereafter, p-values reported 
from the statistical test and the markers with the corresponding p-values are smaller 
than the p-value cut-off, such as 0.01 or 0.05, are selected as the significant correlated 
markers. Table 2-2 lists the implementation of R scripts to calculate the correlation 
coefficient using Pearson moment correlation coefficient and Spearman rank 
correlation coefficient. Table 2-3 lists the implementation of R scripts to identify 
Type-I markers which are significantly correlated with the rank of response class for 
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three classes. As we extend the number of fuzzy clusters of the chemo-response data 
from three classes to “N(N>3)” classes, the R code should be easily modified to 
generate the significantly correlated markers. On the other side, when we degenerate 
the number of the classes from three classes to two classes, the significantly correlated 
markers should give similar results as other procedures, like t-test, SAM and Limma, 
with same FC threshold and p-value cutoff. 

























E: expression of gene i in n samples; Y: the rank of response class from fuzzy 
classification of chemo-response data; E andY , Es and Ys are the mean and standard 
deviation of E and Y respectively. 
 




Table 2-2: The implementation of R scripts to calculate Pearson moment correlation 
coefficient and Spearman rank correlation coefficient 
### Estimate the correlation coefficient between the expression of the potential marker and the 
rank of class from fuzzy classification of chemo-response data 
Correlation.ExprArray.ResponseClass = function(ExprArray,ResponseClass,Method) 
{ 
    CorrelationCoefficient = vector('numeric',length(nrow(ExprArray))) 
    PValue.test          = vector('numeric',length(nrow(ExprArray))) 
    for (i in 1:nrow(ExprArray)) 
    { 
        if (Method=="pearson" )  
        {    
              CorrelationCoefficient.ithMarker = 
cor.test(ExprArray[i,],as.numeric(ResponseClass),method="pearson") 
        } 
        if (Method=="spearman")  
        {      
             CorrelationCoefficient.ithMarker = 
cor.test(ExprArray[i,],as.numeric(ResponseClass),method="spearman") 
        }            
        CorrelationCoefficient[i] = CorrelationCoefficient.ithMarker$estimate        
        PValue.test[i]          = CorrelationCoefficient.ithMarker$p.value  
    } 
    return(list(CorrelationCoefficient,PValue.test)) 
} 




Table 2-3: The implementation of R scripts to identify Type-I markers which are 
significantly correlated with the rank of class from fuzzy classification of the 
chemo-response data (three fuzzy classes in this instance) 
The type-II markers are basically the combination of N sets of significantly 
differentiated markers. For three classes, the type-II signature markers are the 
combination of markers(sensitive), markers(medium) and markers(resistant). Table 
2-4 lists the R scripts to develop markers(sensitive) that are only significantly 
Class  = Response.FuzzyClassification 
Class[which(Response.FuzzyClassification =="Sensitive")] = 2 
Class[which(Response.FuzzyClassification =="Medium")]  = 1   
Class[which(Response.FuzzyClassification =="Resistant")] = 0   
Class = matrix(as.numeric(Class),nrow=1) 
rownames(Class) = "Classes" 
colnames(Class) = toupper(SamplesNames) 
### Filtering with Fold Change metric 
Min.LogFC  = FC.Threshold 
Q.Expr  = vector(length=nrow(ExprArray.PreProcessed)) 
u2 = apply(ExprArray.PreProcessed[,which(Class==2)],1,mean) 
u1 = apply(ExprArray.PreProcessed[,which(Class==1)],1,mean) 
u0 = apply(ExprArray.PreProcessed[,which(Class==0)],1,mean) 
fc2_1 = u2-u1   
fc1_0 = u1-u0 
ExprArray = ExprArray.PreProcessed [which((abs(fc2_1) >= Min.LogFC)&(abs(fc1_0) >= 
Min.LogFC)),]    
### Extracting the significantly correlated genes 
PValue.Cutoff = 0.05 
Correlation = Correlation.ExprArray.ResponseClass(ExprArray,t(Class),"pearson") 
SigGene.ExprArray = ExprArray[Cor[[2]] < PValue.Cutoff,] 
Sig.Correlation = matrix(Cor[[1]][Cor[[2]]< PValue.Cutoff],ncol=1) 
colnames(Sig.Correlation) = "CorrelationCoefficient"  
GXP.Signature = cbind(Sig.Correlation, SigGene.ExprArray) 




colnames(UpDown) = "StatusOfExpression" 
GXP.Signature = cbind(UpDown,GXP.Signature) 
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over-expressed in sensitive samples, but are significantly under-expressed in both 
medium and resistant samples. Similarly, we can modify the scripts to obtain another 
two subsets of signature markers: markers(medium) are only significantly 
over-expressed in medium samples, but significantly under-expressed in both 
sensitive and resistant samples; markers(resistant) are only significantly 
over-expressed in resistant samples but significantly under-expressed in both sensitive 
and medium samples. 
 
Table 2-4: The implementation of R scripts to identify markers(sensitive) of Type-II 
markers which are significantly over-expressed in sensitive samples but 
under-expressed in medium and resistant samples (three fuzzy classes in this instance) 
### Step a: Developing marker(sensitive)：markers are significantly over expressed in sensitive 
sample but under expressed in both medium and resistant samples 
Min.LogFC  = LogFC.Cutoff 
FDR = FDR.Cutoff 
Q.Expr = vector(length=nrow(ExprArray.PreProcessed)) 
Class.S.MR = Response.FuzzyClassification 
Class.S.MR[which(Class=="Sensitive")] = 1 
Class.S.MR[which((Class=="Medium")|(Class=="Resistant"))] = 0   
Design = cbind(mean = 1, diff = as.numeric(Class.S.MR)) 
u2 = apply(ExprArray.PreProcessed[,which(Class.S.MR ==1)],1,mean) 
u1 = apply(ExprArray.PreProcessed[,which(Class.S.MR ==0)],1,mean) 
fc  = u2-u1 
FC.Expr = ExprArray.PreProcessed[which(fc>= Min.LogFC ),]   
fit1  = lmFit(FC.Expr, design) 
fit2  = eBayes(fit1) 
maxNum.probesets = min(nrow(FC.Expr),300) 
topGenes  = topTable(fit2, coef = "diff", number=maxNum.probesets, adjust.method = "BH", 
sort.by="logFC") 
SigGenes.Sensitive = topGenes[which(topGenes$adj.P.Val<FDR),] 
SigGenes.Expr = FC.Expr[SigGenes.Sensitive $ID,] 
GeneType = matrix(rep("SenGenes",nrow(SigGenes.Expr)),ncol=1) 
Feature.Expr = cbind(GeneType, SigGenes.Sensitive[,c("adj.P.Val")], SigGenes.Expr) 
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Following the example of Paclitaxel, we have clustered 52 NCI60 solid tumor 
cell lines into three fuzzy classes. We then coupled the classified chemo-response data 
with microarray data (Affymetrix U133) to develop both type-I and type-II gene 
expression signatures. With the cutoff of LogFC=0.6 and the threshold of 
p-value=0.05, the developed type-I gene signature (Figure 2-6) includes 43 
Affymetrix probesets (8 up, 35 under expressed in sensitive cell lines). This 
developed type-I gene signature show significantly correlated expression with the 
chemo-response of sensitive, medium and resistant samples. With the cutoff of 
LogFC=1 and the minimum of FDR=0.1, the type-II gene signature (Figure 2-7) 
includes 179 Affymetrix probesets (27 genes(sensitive) noted as “SenGenes”; 85 
genes(medium) noted as “MedGenes”; 67 genes(resistant) noted as “ResGenes”), that 
clearly describes the over-expression pattern in the corresponding “class” samples. 
In these two developed signature marker sets, we found that 16 genes appear 
in both type I and type II marker sets and show significant over expression in 
Paclitaxel resistant cell lines: TGM2, MYL9, IGFBP7, GSTM3, SIRPA, TIMP2,  
GNG11, UGCG, HOXB2, TFPI2, OGFRL1, TIMP2, PLEKHA2, PRKCE, C7orf29, 
IGFN1. The basic hypothesis we may form is these 16 probable genes maybe related 
with mechanism of resistance of Paclitaxel. We then performed the gene ontology 
analysis using Ingenuity Pathway Analysis (IPA) tool. As shown in Figure 2-8, the 
analysis has indicated that the mechanism of Paclitaxel resistance may be affected by 
altered drug metabolism and cellular movement. Although, researchers have 
presented the drug metabolism could inactive cytotoxic anticancer agents, like 
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Paclitaxel [117], these 16 genes may have more comprehensive roles in cell 
proliferation. In Figure 2-9, the enriched molecular network also shows that the 
protein signaling pathway is seemingly active as well. 
 
 
yellow: high value; blue: low value 
Figure 2-6: Gene expression pattern of Paclitaxel(NCI60) type-I chemo-response 
signature for three classes: sensitive, medium and resistant samples 
 




yellow: high value; blue: low value 
Figure 2-7: Gene expression pattern of Paclitaxel(NCI60) type-II chemo-response 
signature for three classes: sensitive, medium and resistant samples 




Figure 2-8: Gene ontology analysis of 16 Paclitaxel signature genes which are over 
expressed in Paclitaxel resistant cell lines (IPA content version: 11631407) 
 
Figure 2-9: Core network analysis of 16 Paclitaxel signature genes which are over 
expressed in Paclitaxel resistant cell lines (IPA content version: 11631407) 
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2.4 Test the randomness and uniqueness of the developed signature 
markers 
Before we apply the developed signature markers to predict the 
chemo-response of the anticancer agent(s), the critical questions we need to answer 
are: “Is the signature randomly present in the test data?” and “How is the uniqueness 
of the signature in the test data”? It is hard to answer these questions if we analyze the 
complex biology of the whole signature gene set. Instead, we could borrow a 
statistical metric of the correlation between two matrices known as “Mantel statistics” 
to evaluate the uniqueness of the developed signature markers in the test data. 
The Mantel test is commonly used in ecology estimate the distance between 
objects such as species of organisms. In statistics, the Mantel test[118] allows linear 
or monotonic comparisons between the elements of two distance matrices. The null 
hypothesis of Mantel test is there is no relation between the two square matrices X 
and Y. The values within each matrix (Xij or Yij) represent a relationship between 
points i and j. The relationship represented by a matrix could be a geographical 
distance, a data distance or any other conceivable data. The basic statistics of Mantel 
test is using Mantel Z metric, which is simply the sum of the products of the 
corresponding elements of the matrices: 
ij
ij
ijYXZ  Eq 2-7 
Where ∑ is the double sum over all i and all j where i ≠ j. Because Z can take any 
value depending on the exact nature of X and Y, the Mantel Z metric is usually 
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normalized to -1 to 1, as the correlation coefficient between the pair-wise elements of 
X and Y. Therefore, the Mantel metric may be interpreted as a parameter which is 
similar to correlation coefficient. The original Mantel test[118] gives unbiased test 
statistics that could reveal whether two matrices are significantly similar or not by 
randomly permuting the rows and columns of one of the matrices many times over. 
Since we have only one developed signature, the global measure of similarity of the 
expression signature and only a set of random genes will not be enough to indicate the 
uniqueness of the gene expression signature in the test dataset. Hence, we randomly 
chose many random expression signatures to evaluate the distribution of the Mantel 
metric Z estimated as the similarities between the actual expression signature and 
random expression signatures (noted as ZAR). Similarly, we can also create a baseline 
distribution of the Mantel metric Z between one random expression signature and 
another random expression signature (noted as ZRR). Thus the null hypothesis of our 
test is: 
H0:      RRAR ZZ   Eq 2-8 
Here, we rephrase both ZAR and ZRR: 
ZAR: the similarity metric between the actual expression markers set and random 
expression markers set 
ZRR: the similarity metric between the random expression markers set and another 
random expression marker set 
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After sampling large number of random signatures, with assuming both ZAR 
and ZRR follow Gaussian distribution, we test the significance of the hypothesis H0 
using simple t-test statistics. 
Table 2-3 lists the implementation of R scripts to evaluate the uniqueness of 
the developed signature makers in the test data. The Mantel Z statistics is calculated 
using “mantel.randtest” function in R package “ade4”(version 1.4-17). Figure 2-8 
depicts the uniqueness test results of Hoeflich Mek[119] gene expression signature in 
Bittner breast cancer data. The Mek gene expression signature are composed of genes 
significantly differentially expressed between transfected HRas or Mek MCF-10A 
cell lines and MCF-10A cell lines[119]. The distribution of the Mantel similarity 
between the actual Hoeflich Ras/Mek pathway signature and the sampled random 
gene signatures is significantly lower than the baseline distribution which is defined 
as the Mantel statistics metric among random gene signatures. The unique presence of 
Ras/Mek pathway signature in breast cancer tumor samples is consistent with the 
existing preclinical and clinical studies[119-121]. However, the results from 
uniqueness test of Hoeflich Ras/Mek pathway signature in NCI60 suggest that the 
Hoeflich Ras/Mek pathway signature behaves randomly in NCI60 cell lines (Figure 
2-9). This may due to the observation that basal-like breast cancer tumors cells are 
more dependent on Ras-Mek pathway activity compared with other cancer tumors. 
This is why the Hoeflich Ras/Mek pathway signature is predominantly present in 
breast cancer tumors[119]. Further studies have shown that the Mek inhibition is 
determined by elevated Ras signal and the feedback signaling of MAPK/ERK Kinase 
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(MEK)-Phosphoinositide 3-Kinase[122]. The predicted results of Hoeflich Ras/Mek 
gene signature in both datasets have shown that the pattern of the signature in Bittner 
Breast cancer data is clear: about 50% of the breast cancer samples have shown active 
Ras-Mek pathway when compared with the rest of the samples. However, the pattern 
of the signature in NCI60 cell lines is relatively very weak as only about 10-20% of 
cell lines show that the Ras-Mek pathway is active. 
 
Table 2-5: The implementation of R scripts to test the uniqueness of the signature 
markers in the test data using Mantel statistics metric 
#############################################################
### 
### test the uniqueness of gene signature in test data 
obs_vector_Actual_Rnd = vector("numeric",length=0) 
obs_vector_Rnd_Rnd    = vector("numeric",length=0) 
# The actual signature markers in test data 
exprData.bioMarker.Actual = exprData.bioMarker 
# the random signature markers in test data 




for (iter in 1:n.permutation) 
 {    
     exprData.bioMarker.Rnd  = 
dataset.Matrix[sample(dim(dataset.Matrix)[1])[1:dim(exprData.bioMarker)[1]],] 
     exprData.bioMarker.Rnd1 = 
dataset.Matrix[sample(dim(dataset.Matrix)[1])[1:dim(exprData.bioMarker)[1]],] 
     # set nrepet to 10 as we are not interested in the emperical p-value of the test       
     mantel.bioMarker.Act = mantel.randtest(dist(t(exprData.bioMarker.Actual),method=Metric), 
dist(t(exprData.bioMarker.Rnd),method=Metric),nrepet=10) 
     mantel.bioMarker.Rnd = mantel.randtest(dist(t(exprData.bioMarker.Rnd1),method=Metric), 
dist(t(exprData.bioMarker.Rnd),method=Metric),nrepet=10) 
 # Aggregate the Mantel metric from a random selected genes/probesets compared to  
   # another randomly selected genes/probesets   
obs_vector_Rnd_Rnd    =  c(obs_vector_Rnd_Rnd, as.numeric(mantel.bioMarker.Rnd$obs)) 




Figure 2-10: Hoeflich Ras/Mek pathway gene expression signature is uniquely 
present in Bittner breast cancer tumor samples (p.value<0.001) 
 
Figure 2-11: Hoeflich Ras/Mek pathway gene expression signature is randomly 
present in NCI60 cell lines data (p.value=0.953) 




Figure 2‐12: Hoeflich Ras/Mek pathway gene expression signature in Bittner Breast 
cancer datasets; samples are sorted by the predicted probability of activity using 








Figure 2-13: Hoeflich Ras/Mek pathway gene expression signature in NCI60 cell line 
datasets; samples are sorted by the predicted probability of activity using Bayesian 
Metagene projection methods[79]. 
2.5 Signature detection method 
After we assessed the developed signature markers that are uniquely present in 
the test data, the following step is to discover the expression pattern of the signature 
markers in the test data. The problem with these types of analyses is that the number 
of signature markers usually range between tens to hundreds. This, however, does not 
allow us to study all the markers individually in order to detect each gene’s expression 
pattern specifically. Bioinformatics algorithms that can manipulate the overall 
signature markers are needed. Generally, there are two types of methods: supervised 
Up 
Down 
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and unsupervised. By employing the unsupervised method, the patterns of the 
expression signature in the test data are inherently determined without a priori 
information. Typical algorithms include relevance networks[123, 124], hierarchical 
dendrograms and self organizing maps[125, 126], and all these algorithms require a 
metric, such as Euclidean distance, correlation coefficient or mutual information 
between the markers. The end result of unsupervised analysis of the expression 
signature in the test data is the agglomerative clusters information of samples and 
signature markers. Another type of the analysis is supervised learning. By using the 
context of signature development in the training data, parameters in the models, such 
as support vector machine (SVM)[127, 128], neural network[129] and decision 
trees[130], can be determined and then used to predict samples in the test data. 
Although the characterization of the signature expression in the test data is 
interesting, it is more important to address the issue on how much is the biological 
pattern(s) of the expression signature in the training data remained in the test data. 
Therefore, a statistical method is necessary to quantitatively measure the extent of 
how the pattern remained in the test data. The metagene methodologies have proven 
to be capable in capturing the phenotypic patterns of the expression data[131-134]. 
The concept of metagene projection was originally presented by West et al.[79], and it 
has demonstrated to be useful in predicting the expression pattern that remained in 
cross platforms[135]. West et al. also proposed a statistical method which integrated 
standard binary regression models, singular value decomposition(SVD) and metagene 
projection to measure the extent of the expression pattern of training data remained in 
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the test data. Here for simplicity, we name it as “Bayesian-SVD” method. The 
developed signature data is constructed with samples in columns and markers in rows. 
Principal components of the training data are used to compute the metagene and 
metasample values, and then form metagene signature. The expression signature in 
the test data is then projected into this metagene signature. The projected metagene 
signature retains the most information of the signature expression pattern in the test 
data. West et al.[79] used Bayesian binary probit regression model to generate the 
probability of the remaining signature pattern for two classes problem. We name the 
predicted probability of the chemo-response signature as the probability of sensitivity 
(POS) and the predicted probability of pathway or oncogene activity signature as the 
probability of activity (POA). The model was fitted to the metagene signature and 
relative probability of sensitivity (POS) or probability of activity (POA) is estimated 
to the projected metagene expression signature using the Bayesian binary probit 
regression parameters fitted from the metagene signature. When studying 
chemo-response predictor, the classes are defined as ‘0’ for resistant and ‘1’ for 
sensitive for training. Low POS scores would be suggestive of a sample being 
resistant and vice versa. When studying pathway or oncogene predictors, the classes 
are defined as ‘0’ for hypoactive and ‘1’ for hyperactive. The critical issue of 
Bayesian-SVD method is we could only use the major singular value instead of all 
non-zero singular value in the application of microarray data analysis due to the large 
scale of microarray data. The Bayesian-SVD method may lose some information in 
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the training data. Therefore, we introduce another metagene projection method as 
follows and which is named as Bayesian-NMF method. 
 
Figure 2-14: The schematic flow chart of detecting the expression signature in the 
test data using Bayesian-SVD metagene projection method. MTr: the marker genes in 
the original training dataset, MTe: the marker genes in the test dataset, FTr: metagene 
expression, FTe: projected metagene expression. 
In this dissertation, we present a novel method to detect the expression 
signatures in the test datasets by assigning the predicted probability to each sample. 
The novel computational method is based on Non-Negative Matrix Factorization 
(NMF). NMF is basically a type of an Independent Components Analysis (ICA) 
variant with the restriction(s) to positive values[136]. The feature of non-negativity of 
the decomposed matrix elements facilitates the NMF method such that it can be 
widely used in genomic data analysis[137-140]. In contrast to Principal Component 
Analysis (PCA) or Singular Value Decomposition (SVD) and other ICA-based 
methods, the negative metagene expression is inherently close to the interpretation of 
Chapter 2 A systematic bioinformatics methodology to develop principle markers 
84 
 
gene or protein expression. The NMF method permits the decomposed matrix to be 
sparse and it also permits localized features[136, 139], which means that the NMF 
may capture the critical expression information of the genes, such as oncogene genes 
or tumor suppressor genes in cancer research. This feature suggests the NMF method 
is superior to the PCA and other ICA based approaches. The NMF algorithm usually 
gives local optimizations, and this seems more suitable for the biological systems 
which essentially have multiple stable points after perturbations. This framework 
combines the Bayesian regression method, the NMF method and the metagene 
projection method.  
Consider a gene expression data set consisting of the expression levels of N 
features (genes or probesets) in S samples, which represents different types of 
experiments or experiment time points. For gene expression signature, the number N 
features is typically in the hundreds, and the number S experiments is typically less 
than 100. We refer the gene expression signature datasets by an expression matrix X 
of size N by S, whose rows contain the expression levels of the N features in the S 
samples. The Non-negative Matrix Factorization decomposes the matrix X into the 
multiplication of two small sized matrices, and each of them with non-negative 
elements. The NMF method is the approximation of the positively linear 
combinations of metagene expressions, which is defined as “factor matrix”. Formally, 
the standard NMF is described as follows:  
H WNMF: X   Eq 2-8 
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X corresponds to the gene expression signature with size N by S, W is the factoring 
matrix with non-negative entities, it has size N by k, with each of the k columns 
defining a metagene or factor; entry Wij is the coefficient of gene i in metagene j. The 
loading of matrix H has size k by S, with each of the M columns representing the 
metagene expression pattern of the corresponding sample; entry Hij represents the 
expression level of metagene i in sample j.  
The NMF decomposition is usually done by an iterative updating method. The 
multiplication updating rule was proposed by Lee and Seung (1999).  
  



























To enhance the sparse of the metagene expressions, Pascual-Montano et al. 
(2006) proposed a non-smooth NMF method by adding sparseness constraints to the 
Lee and Seung’s NMF procedure. Mathematically, Pascual-Montano et al. defined a 







Where I is the identity matrix, V1 is a vector of ones and the parameter  represent 
the sparseness, which satisfies 10   . Therefore, the Non-smooth Nonnegative 
Matrix Factorization model was defined as: 
HS WnsNMF: X   Eq 2-11 
The nsNMF method can be quickly implemented by following Lee and 
Seung’s updating rule. Correspondingly, in the update equation for H, substitute W 
with WS and in the update equation for W, substitute H with SH. Table 2-4 lists the 
detailed implementation of NMF algorithm with Lee and Seung’s multiplicative 
updating rule.  




Figure 2-15: The schematic flow chart of detecting the expression signature in the 
test data using Bayesian-NMF metagene projection method. MTr: the marker genes in 
the original training dataset, MTe: the marker genes in the test dataset, HTr: metagene 
expression, HTe: projected metagene expression. 
Figure 2-15 depicts the flow chart of using Bayesian-NMF metagene 
projection method to detect the expression signature in the test data. Figure 2-16 and 
Figure 2-17 describe the detection results of Bild Ras[141] oncogene activity 
signature in Ding lung[142] primary tumor and Bhattercharjee Lung[143] primary 
tumor data respectively. Both shows AUC is significantly greater than 0.5 when 
comparing the predicted activity of Ras activity in K-Ras mutants and wild type 
samples, which indicate that the presented Bayesian-NMF metagene projection 
method is able to detect the expression signatures in an unbiased way. In order to 
compare the performance of the Bayesian –NMF method, Figure 2-18 depicts the 
detection results of Bild Ras[141] oncogene activity signature in Bhattercharjee 
Lungprimary tumor data using Bayesian-SVD method. The Bayesian-NMF method 
shows very similar detection results with Bayesian-SVD method in terms of AUC 
metric. Although the example shown here reflects only two class problems, the 
dimension of the NMF decomposed matrix can be three or more, based on the 
Chapter 2 A systematic bioinformatics methodology to develop principle markers 
87 
 
response class information and the optimal solution from NMF algorithm. Therefore, 
this method can be applied to multiple class problems as well. 




Table 2-6: R scripts of the implementation of NMF algorithm (Lee and Seung’s 
updating rule) 
### NMF algorithm: Lee and Seung’s updating rule 
NMF = function(M,r) 
{   # M is the original matrix for factorization;  r is the lower dimension and r < 
min(nrow(M),ncol(M)) 
    connect   = min(50,nrow(M))  # converge condition 1 
    tol.converge = 1.0e-6           # converge condition 2 
    tol = 1.0e-8                    # small positive number 
    # Initialize factorization matrices W,H 
    n.row = nrow(M);  n.col = ncol(M);  r = min(r,n.row,n.col) 
    mean.M =sqrt(mean(M));   sd.M = mean(sd(M)) 
    nmf.M = list() 
    W0 = matrix(runif(n.row*r),n.row,r);     H0 = matrix(runif(r*n.col),r,n.col)      
   Flag = 1;  Iter = 1;  Obj = NULL 
    while(flag==1) 
    {    H0[H0<0] = tol;  W0[W0<0] = tol 
        # Compute new W and H (Lee and Seung) 
        W1 =W0*(M%*%t(H0)/(W0%*%H0%*%t(H0)+tol)) 
        H1 = H0*(t(W1)%*%M/(t(W1)%*%W1%*%H0+tol))         
        # Renormalize so rows of H have constant energy 
        norms = sqrt(apply(H1^2,1,sum)) 
        H1   =  H1/matrix(rep(norms,n.col),ncol=n.col);   W1  =  
W1*t(matrix(rep(norms,n.row),nrow=r))         
        order.W1 = order(W1,decreasing=T);       order.H1 = order(H1,decreasing=T)         
        order.W0 = order(W0,decreasing=T);       order.H0 = order(H0,decreasing=T) 
        sum.obj0 = sum(abs(M-W0%*%H0));       sum.obj1 = sum(abs(M-W1%*%H1)) 
        if 
(((sum(abs(order.W1[1:connect]-order.W0[1:connect])))==0)&((sum(abs(order.H1-order.H0)))=
=0) &(abs(sum.obj0-sum.obj1)<1.0e-3)) 
        {    abs.H.dif   = abs(H1-H0) 
             order.H.dif = order(abs.H.dif,decreasing=T) 
             if (((abs.H.dif[order.H.dif[1]]/H1[order.H.dif[1]])<tol.converge)& 
               ((abs.H.dif[order.H.dif[2]]/H1[order.H.dif[2]])<tol.converge)& 
               ((abs.H.dif[order.H.dif[3]]/H1[order.H.dif[3]])<tol.converge)) 
               {    flag = 0;        print('NMF is converged!')     }      }          
        W0  = W1;         H0 =  H1 
        Iter  =  Iter+1 
        Obj  = c(Obj,sum.obj1)   }  
        SSE = sum((M-W1%*%H1)^2) 
        nmf.M$W = W1;    nmf.M$H  = H1 
        nmf.M$SSE = Obj;  nmf.M$Iteration = Iter 
        return(nmf.M)   } 




sd.AUC: Standard deviation of AUC estimate, p.val: Probability (null hypothesis: the 
expression signature is non-informative) 
Figure 2-16: Receiver Operating Characteristic (ROC) curve of detecting Ras 
pathway expression signature in Ding Lung[142] primary tumor data using 
Bayesian-NMF method. In ROC plot, samples with K-Ras mutation and K-Ras wild 









sd.AUC: Standard deviation of AUC estimate, p.val: Probability (null hypothesis: the 
expression signature is non-informative) 
Figure 2-17: Receiver Operating Characteristic (ROC) curve of detecting Ras 
pathway expression signature in Bhattercharjee Lung[143] primary tumor data using 
Bayesian-NMF method. In ROC plot, samples with K-Ras mutation and K-Ras wild 
type were compared, AUC=0.67±0.06. 




sd.AUC: Standard deviation of AUC estimate, p.val: Probability (null hypothesis: the 
expression signature is non-informative) 
Figure 2-18: Receiver Operating Characteristic (ROC) curve of detecting Ras 
pathway expression signature in Bhattercharjee Lung[143] primary tumor data using 
Bayesian-SVD method. In ROC plot, samples with K-Ras mutation and K-Ras wild 
type were compared, AUC=0.68±0.07. 
2.5 Summary 
We have reviewed a couple of methods to develop expression signature 
markers for two class problems. By suggesting a concept of fuzzy classification, it is 
very necessary to develop expression signature markers for three and more classes. 
Hence, two types of expression signature markers are proposed, and the 
corresponding development methods are also presented. The expression signature 
may be randomly and no uniquely present in the test data; therefore, we suggested a 
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computational method by borrowing a statistic metric of measuring a similarity of two 
matrices to evaluate the uniqueness of the signature in the test data. Lastly, in order to 
detect the signature in a more robust way, we proposed a novel framework that we 
call the Bayesian-NMF metagene projection method. The overall methodology of 
expression signature development, uniqueness test, and detection is systematic and 
robust.  
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Chapter 3 Identifying minimal marker sets 
for clinical translation 
3.1 Introduction 
In chapter 2, we proposed a systematic bioinformatics methodology to develop 
the principle expression chemo-response markers, by which the markers, based on 
say, gene expression, microRNA etc., are significantly differentiated between two 
class samples, or are correlated with multiple class samples that can be identified and 
utilized to predict agents’ chemo-response in independent cancer data. These 
signature markers that correlate with a phenotype of interest have shown to play very 
important roles in cancer research and clinical prognosis[144-168]. However, it is still 
very challenging to move multiple-gene signature into clinical application, the efforts 
for assay development, optimization and further in-vitro, in-vivo, and clinical 
validations many take a lot of time and resources. Therefore, narrowing down the 
multiple gene/protein signature from tens to hundreds of markers to a minimal gene 
marker set (<10) or even a single gene marker is usually requested and welcomed by 
clinicians.  
Since cancer is driven by the alterations of various cell signaling, cellular and 
physiological processes, it is essential to systematically understand the corresponding 
heterogeneous genomic biology of the expression markers, such as mutations, copy 
number variation or methylation, and regulations between transcripts or proteins and 
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miRNAs. One type of integrated analysis of genomic data is the meta-analysis, which 
is an analysis often applied to multiple similar datasets in clinical practice to classify 
tumor types and identify robust prognosis markers[169-172]. In order to narrow down 
the multiple-gene signature rigorously, it is essential to decode the over or under 
expression for each expression marker, such as transcripts or proteins, using the 
corresponding sequence genomics data, copy number variation, methylation data and 
miRNA data. Recently, there have been a number of integrated genomic analyses 
between gene expression profiling and DNA copy number variation, gene mutation, 
DNA methylations, microRNA expression and protein expression have been 
reported[173-181]. 
Beyond the various types of integrated analysis that have been applied in 
cancer data, a range of computational models have also been suggested. The most 
popular method is the correlation coefficients, which is applied to integrate DNA 
copy number and gene expression[182, 183], and methylation and gene 
expression[184] etc. The correlation based method captures simple pair wise relations 
of one type of genomic aberrations and its effect on the expression of the marker, but 
this may limit the understanding of the whole picture. Relating multiple genetic 
aberrations information with phenotypic expression helps to better comprehend the 
mechanism of cancer phenotypes. Therefore, a coherent model that combines 
different types of genetic aberration data is inevitably needed. The coherent model is 
expected to optimize the number of signature markers by identifying the most 
representative marker, enabling it to shift quickly into clinical applications. 
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3.2 Integrated genomic analysis using linear model 
We propose a mathematical model to describe how genetic aberrations change 
the expression of the each single signature marker. Let iy  the expression of the 
signature marker i, such as gene expression or protein expression, and its value is 
numeric (log2 transformed signal); iMu is the mutation of marker gene i and its value 
is integer with -1 for frame shift deletion or homozygous deletion, 0 for wild type and 
1 for point mutation or other types of activation mutation; iCNV  is the DNA copy 
number of gene i and its value is numeric with or without normalized by the HapMap 
reference value; iMe is the methylation of gene (or promoter) i and its value is 
between -1 to 0. Recall the Eq 1-1 introduced in chapter 1, we obtain 
 iiii Me,MuCNVfy ,  Eq 3-1 
 Consider the combinational effects of copy number variation, mutation and 
methylation is linear, then 
0,,,, 32103210  aaaaMeaCNVaMuaay iiii  Eq 3-2 
By using linear programming techniques, we could identify the genes whose 
expressions are significantly driven by genomic aberration. For example, here we 
chose CDKN2A as the example to study this model. CDKN2A is one of the marker 
genes from our generated Paclitaxel chemo-sensitivity gene signature and it has 
known role as a biomarker for G2M anticancer agents[185]. Therefore, CDKN2A 
could be one of the most representative single gene maker to reflect the 
chemo-response of Paclitaxel in NCI60 data. Figure 3-1 describes CDKN2A gene 
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expression relates to the mutation and methylation. According to the plot, CDKN2A 
homozygous mutation samples show a very low expression of CDKN2A and wild 
type samples with low methylation show a very high expression. Figure 3-2 depicts 
the CDKN2A mRNA expression and the coded protein p16 expression; both of them 
are highly correlated except the wild type samples with high methylation, which tend 
to show significant low expression. Table 3-1 lists the detailed gene expression data 
of CDKN2A (Affymetrix U133(A&B) array, log2-transformed MAS5), and the 
genetic information which include mutation (COSMIC database v52), DNA copy 
number variation and CpG island methylation data (CellMiner v1.0). Table 3-2 lists 
the estimated parameters for CDKN2A gene fitted in model Eq 3-2. According to the 
statistical analysis, it is obvious that both CDKN2A mutation and CpG island 
methylation significantly affect the gene expression of CDKN2A gene. 
Cell Line Classes mRNA Mut CNV Me.CpG AA Change 
SK_MEL_2 Sensitive 10.13 0 -0.5 0.4 WT 
LOXIMVI Sensitive 8.17 -1 -1.03 0 p.M1_ *157del 
SW620 Sensitive 11.89 0 -0.09 0.89 WT 
NIH.OVCAR_3 Sensitive 12.96 0 0.69 0 WT 
NCI_H522 Sensitive 12.78 0 0.24 0 WT 
MDA_MB_435 Sensitive 11.04 1 0.61 0 p.? 
HCT_116 Sensitive 10.54 1 -0.13 0.57 p.R24fsX20 
HCC_2998 Sensitive 12.04 0 0.25 0 WT 
SNB_75 Sensitive 11.74 0 -0.49 0 WT 
NCI_H460 Sensitive 7.04 -1 -0.83 1 p.? 
MCF7 Sensitive 9.03 -1 -0.04 0 p.M1_ *157del 
M14 Sensitive 10.22 1 0.88 0 p.? 
OVCAR_8 Sensitive 11.88 0 0.62 0 WT 
KM12 Sensitive 12.62 0 0.58 0.84 WT 
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UACC_62 Sensitive 7.52 -1 -0.57 0 p.M1_ *157del 
NCI_H322M Sensitive 6.61 0 -1.22 1 WT 
PC_3 Sensitive 11.84 0 -0.39 0.89 WT 
U251 Sensitive 7.37 -1 -1.17 1 p.M1_ *157del 
COLO_205 Medium 10.56 0 0.12 0.96 WT 
A549 Medium 8.24 -1 -0.7 1 p.M1_ *157del 
SF_539 Medium 12.08 0 0.69 0 WT 
HS578T Medium 5.13 -1 -0.19 1 p.M1_ *157del 
SK_OV_3 Medium 8.34 -1 -1.64 0 p.? 
DU_145 Medium 13.41 1 0.06 0 p.D84Y 
SK_MEL_5 Medium 7.93 -1 -1.48 0 p.M1_ *157del 
RXF_393 Medium 7.17 -1 -1.65 0 p.M1_ *157del 
BT_549 Medium 13.58 0 0.53 0 WT 
SNB_19 Medium 7.26 -1 -0.32 1 p.M1_ *157del 
HOP_62 Medium 6.11 -1 -0.11 1 p.M1_ *157del 
SN12C Medium 12.93 0 -0.2 0 WT 
IGROV1 Medium 9.27 0 -0.32 0 WT 
OVCAR_5 Medium 7.09 -1 -1.45 0 p.M1_ *157del 
SF_295 Medium 6.88 -1 -0.44 1 p.M1_ *157del 
MDA_MB_231 Medium 5.98 -1 -0.31 1 p.M1_ *157del 
X786_0 Medium 5.34 -1 -0.98 1 p.? 
SF_268 Medium 4.56 -1 -1 1 p.M1_ *157del 
A498 Resistant 7.58 -1 -1.36 1 p.M1_ *157del 
T47D Resistant 10.25 0 0.14 0.9 WT 
TK_10 Resistant 12.26 0 -0.02 0.81 WT 
UACC_257 Resistant 10.80 0 -0.27 0 WT 
CAKI_1 Resistant 6.82 -1 -0.71 0 p.M1_ *157del 
HOP_92 Resistant 9.94 -1 -0.1 0 p.M1_ *157del 
MALME_3M Resistant 6.38 -1 -0.79 0 p.M1_ *157del 
SK_MEL_28 Resistant 10.97 0 -0.64 0 WT 
HCT_15 Resistant 6.65 0 0.64 1 WT 
EKVX Resistant 10.81 0 0.11 0.85 WT 
NCI_H226 Resistant 7.36 -1 0.85 0 p.? 
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UO_31 Resistant 8.16 -1 0.6 0 p.M1_ *157del 
NCI_ADR_RES Resistant 13.62 0 0.58 0 WT 
ACHN Resistant 6.71 -1 -1.61 0 p.M1_ *157del 
OVCAR_4 Resistant 11.55 0 -0.14 0 WT 
Table 3-1: Gene expression, mutation, DNA copy number variation and CpG 
methylation of CDKN2A. 
 
Figure 3-1:  Jitter plot of the expression of CDKN2A gene (Affymetrix U133A&B 








Figure 3-2:  CDKN2A gene expression (Affymetrix U133A&B array) and CDKN2A 
coded protein expression, p16 with the genomic aberrations 
 
Parameters Estimate SE t-value P-value 
Intercept 11.05 0.31 35.40 <2e-16 
Mut 2.33 0.43 5.39 2.22e-06 
CNV 0.76 0.38 1.99 0.053 
Me.CpG 1.43 0.49 2.92 0.0054 
Table 3-2: Model parameter estimated for CDKN2A gene in the Paclitaxel type-II 
gene signature 
3.3 CDKN2A as the single gene marker for Paclitaxel  
We have identified that CDKN2A has sufficient preliminary criteria to be a 
single gene marker via integrated genomic analysis of gene expression, mutation, 
DNA copy number variation and methylation. We therefore can evaluate the actual 
performance of CDKN2A as a single gene marker of Paclitaxel. Firstly, we plotted 
the jitter plot (Figure 3-1) for CDKN2A expression in 51 NCI60 solid tumor cell lines. 
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As expected, the Paclitaxel sensitive samples show an over-expression of CDKN2A. 
Interestingly, the expression of resistant samples is higher than the medium samples. 
This is understandable, since the original signature is the combination of three sets of 
significantly differentiated genes. Since the GI50 of Paclitaxel sensitive samples is 
10-fold less than the GI50 of Paclitaxel resistant samples, it would be more 
meaningful to assess the predicted ability of CDKN2A to Paclitaxel sensitive and 
resistance. Figure 3-3 depicts the AUC plot to use CDKN2A gene expression to 
predict Paclitaxel sensitive and resistant chemo-response pattern. AUC=0.64 seems 
indicate the CDKN2A is only a weak single gene predictor of Paclitaxel 
chemo-response. 
 




Figure 3-3:  Jitter plot of the expression of CDKN2A gene (Affymetrix U133A&B 
array) in the corresponding Paclitaxel chemo-response classes 
 




Figure 3-4: AUC plot of the expression pattern of CDKN2A in Paclitaxel sensitive 
and Paclitaxel resistant samples 
3.3 General strategies to propose minimal marker sets for 
clinical translation 
The integrated analysis identified the principle expression markers may 
potentially applicable in clinical translation since the expression pattern of each 
marker can be well explained by the related genomic aberrations. Specifically, N-gene 
marker may be requested in the clinical applications. Therefore, we suggest three 
general strategies to narrow down multiple gene signature markers to N-gene marker. 
• Strategy-I: Use the gene markers with the gene or protein expression are well 
explained by the heterogeneous genomic biology using integrated genomic data 
analysis 
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• Strategy-II: Use the combination of N-gene marker set which gives minimal 
misclassification rate 
• Strategy-III: Strategy-I + Strategy-II 
Strategy-I is the aggregation of N genes, such as CDKN2A, whose expression 
are significantly affected by the corresponding gene mutation, CpG island 
methylation and DNA copy number of variation. 
Strategy-II is using a searching algorithm to identify the best combination of N 
genes which gives the minimal misclassification rate. When handling chemo-response 
gene expression signature, a multinomial probit regression model is usually employed 
to assign a predicted probability of each response class for each sample. Consequently, 
the predicted accuracy and error rate is estimated. Table 3-3 depicts the possible 
3-gene marker for Paclitaxel type-II gene signature. According to the table, the best 
combination of 3-genes gives the minimal error rate 0.18 using multinomial probit 
regression. This is done using R package “vbmp” version 1.20.  
Gene 1 Gene 2 Gene 3 Error Rate 
231067_s_at 202685_s_at 204780_s_at 0.18 
203323_at 202685_s_at 204584_at 0.20 
211980_at 228107_at 202897_at 0.22 
214247_s_at 213906_at 204086_at 0.269 
222802_at 202685_s_at 218537_at 0.288 
… … … … 
Table 3-3: The combination of 3 genes marker (Strategy-II) narrowed down from the 
Paclitaxel type-II gene signature 
Strategy-III is the combination of Strategy-I and Strategy-II, which means a 
part of the marker genes are selected from Strategy-I and another part of the marker 
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genes are selected using Strategy-II. For example, if P (P<N) genes are identified by 
integrated genomic analysis and are requested to move into clinical for further 
validation, but the prediction performance is not good, strategy-II can be then 
followed to identify another Q (Q=N-P) genes and the combined N (P and Q) genes 
are expected to give a improved prediction accuracy than P genes. Table 3-4 describes 
the identified 3-gene marker included CDKN2A(209644_x_at) gene for Paclitaxel 
type-II gene signature. The best 3-gene marker (Include CDKN2A) gives error rate 
0.228 that is slightly lower than the error rate reported by 3-gene marker using 
strategy-II. 
Gene 1 Gene 2 Gene 3 Error Rate 
209644_x_at 222108_at 223622_s_at 0.228  
209644_x_at 222108_at 201850_at 0.268  
209644_x_at 202686_s_at 201850_at 0.268  
209644_x_at 202685_s_at 204780_s_at 0.327 
209644_x_at 201951_at 201850_at 0.327  
… … … … 
Table 3-4: The combination of 3 genes marker (Strategy-III) narrowed down from the 
Paclitaxel type-II gene signature 
3.4 Summary and discussions 
In order to narrow-down the size of multiple-marker signature to a small 
number(<10) of signature markers, we have suggested an integrated genomic analysis 
mathematical model to understand how the genetic aberrations regulate the 
phenotypic expression of the marker gene. CDKN2A is selected as the single gene 
marker of Paclitaxel, as it shows that its gene expression is significantly affected by 
mutation and CpG island methylation. However, the AUC analysis has indicated that 
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this single gene predictor is only a weak predictor. Although the single marker 
predictor can be quickly adopted into clinical practices, it may show poor 
predictability when compared with multiple-marker predictors. Alternatively, we 
suggested three general strategies to identify N-gene (N<10) marker for clinical 
translations. 
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Chapter 4 A genomic signature to 
characterize concordant response among 
chemotherapeutics 
4.1 Introduction 
Cancers are complex and heterogeneous diseases characterized by the 
uncontrolled growth and spread of abnormal cells[186]. One of the most commonly 
used treatment option for cancer patients is the treatment with an appropriate 
chemotherapeutic agent or agents. However, one of the biggest challenges associated 
with chemotherapy is that patients with similar histopathology do not consistently 
respond the same way to the same agent. Optimizing the choices of anticancer therapy 
for individual patients using translational research methods is an key challenge to 
clinical practice[187-189]. For our usage, we adopt the definitions for “translational 
science” and “translational medicine” mean “new knowledge, mechanisms and 
techniques generated in basic science research and clinical research that are 
effectively translated into new approaches for prevention and diagnosis, or new 
treatment methods for better healthcare”[190].  
Molecular markers are well recognized as powerful translational tools that 
provide guidance for chemotherapy treatment in a clinical setting. Molecular markers 
may include: a) the gene targets themselves in the case of targeted agents; b) the 
activity of the targeted pathways; and c) genes only indirectly related with the agents 
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or targeted pathway. The drug targets themselves are the most important markers for 
targeted anticancer agents. For example, patients with Her2 amplification show 20% 
higher response rate to Herceptin than patients with HER2 normal copy number[72, 
73]. In addition, the activity of a targeted pathway may also serve as a marker for a 
drug’s clinical response. For example, patients whose tumors contain activating 
mutations in KRas show worse response than patients with wild type KRas to 
Cetuximab and Panitumumab, which are fully human monoclonal antibodies specific 
to the epidermal growth factor receptor (EGFR). This is because an activating KRas 
mutation will lead to constitutively active downstream signaling of the pathway, 
rendering EGFR inhibition ineffective[74, 191]. In addition to drug targeted genes 
and targeted pathways, there are also some molecular markers that are not directly 
related with the targeted pathway. For example, ABCB1, TOP2A, and BCL2 are 
candidates of predictive markers used to predict the response to cytotoxic 
chemotherapy in breast cancer[76]. 
Many anticancer agents, such as cytotoxic drugs that are used to treat different 
cancers, have variable outcomes in patients. For example, only about 20% of patients 
with breast cancer respond therapeutically to the widely used drug taxane (Paclitaxel 
or Docetaxel) [192]. Chemotherapy agents – especially cytotoxic drugs – also cause 
unwanted side effects. Cytotoxic drugs work by killing cells which are dividing, and 
so some non-cancerous cells can be damaged by their action. Since the response rate 
is often low and toxicity is often high, combinations of a cytotoxic drug and other 
chemotherapeutic agents have been developed. Some combinational treatments have 
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become the standard first line treatment in clinical use. Typical examples include 
patients with breast cancer who may be given the “TFAC” (Paclitaxel(T), 
5-Fluorouracil(F), Adriamycin(A) and Cyclophosphamide(C)) treatment, DC 
(Docetaxel and Cyclophosphamide) treatment, or FAC (5-Fluorouracil, Adriamycin 
and Cyclophosphamide) treatment in the neo-adjuvant setting. However, there are two 
challenges which may limit the application of multidrug combinations. First, 
combinations of multiple drugs have increased toxicity over individual agents. The 
administration of ineffective chemotherapy agents in combination regiments with 
relatively higher efficacy rates may increase the probability of side effects and 
decrease the quality of life for many cancer patients. Second, many tumors develop 
multidrug resistance (MDR) to multiple chemotherapy agents. This affects patients 
with a wide variety of blood cancers and solid tumors, including breast, ovarian, lung, 
and lower gastrointestinal tract cancers. Chemotherapy kills drug-sensitive cells, but 
leaves behind a higher proportion of drug-resistant cells. As the tumor begins to grow 
again, chemotherapy may fail because the remaining tumor cells are now resistant. 
MDR has been found to be correlated to the presence of ATP-binding cassette 
transmembrane transporter superfamily proteins, like P-glycoprotein, which may 
expel chemotherapy drugs from the interior of the cell[193]. 
What is needed, therefore, is a way of predicting the response of the cancer 
using molecular markers to a treatment (single agent or a multidrug combination) 
before administering chemotherapy. Such a rational approach to chemotherapy would 
prevent patients from having to undergo chemotherapy treatments that will not have a 
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clinically beneficial outcome. Over the last decade, the use of gene expression 
profiling has changed our understanding of cancer biology and raised the prospect of 
stratifying patients by predicting response to chemotherapy based on gene expression 
signatures. Recent research work has shown that the response in pre-clinical materials 
such as immortalized cell lines can be used to generate genomic signatures (from 
microarray gene expression data) that are predictive of response to a single drug[194]. 
The ultimate purpose of our study is to use preclinical material data to 
establish a systematic framework of anticancer combinations which may be 
effectively administrated to cancer patients. Using a translational genomic method 
similar to previous work[195], we develop genomic signatures for predicting response 
to cytotoxic agents and assess the prediction results of the signature in cell lines and 
patient tumor samples. The preclinical material includes cell lines and assay data from 
NCI-DTP (http://dtnci.nih.gov/) as well as primary human tumor derived explants 
from Oncotest (Germany)[7, 196], that has established a large collection of primary 
human tumor xenografts growing subcutaneously in nude mice. The primary 
xenografts retain many of the characteristics of the parental patient tumors including 
histology and sensitivity to anticancer drugs and to a high extent recapitulate the 
response of the donor patient to standard anticancer drugs[7]. Furthermore, an in vitro 
tumor clonogenic assay (TCA; inhibition of colony formation ability of cells that 
show anchorage independent growth in soft agar) performed on explant material 
derived from the in vivo models is highly predictive of in vivo response)[7, 196].  
Chapter 4 A genomic signature to characterize concordant chemotherapeutics 
110 
 
Predictive biomarkers of response to a particular agent may be difficult to 
distinguish from prognostic biomarkers that predict the outcome of the general 
treatment in a clinical setting, especially when that agent is used in combination. 
Using preclinical assays of sensitivity and translating genomic signatures to predict 
clinical response may partly address this challenge, while raising additional 
challenges of imperfect preclinical models. We hypothesized that the ability to predict 
response with high specificity for individual chemotherapeutic cytotoxic agents may 
be hampered by concordant chemo-sensitivity or chemoresistance in preclinical 
models. In this study, through an integrated analysis of basal microarray expression 
data and preclinical response, we identified a 168 gene expression signature for 
concordance of chemotherapeutic sensitivity. We first define the concordance of 
chemotherapeutics among 14 selected cytotoxic Standard of Care (SOC) anticancer 
agents. We then characterize the concordance of chemotherapeutics using a gene 
expression signature with robust in vitro validation using an independent data set. We 
next detect the developed signature to be present in the clinical patients who were 
treated with (TFAC) combination. This signature of concordant chemotherapeutics 
also shows a prognostic value to identify long survival patient groups in breast cancer 
and lung cancer. 




4.2.1 Concordant chemotherapeutics across 14 cytotoxic agents  
The starting point of this study is the observation of chemotherapeutic 
response in the established in vitro tumor models, such as breast, ovarian, colon, 
renal, lung, prostate, and melanoma cancers. We focused on two independent in vitro 
drug sensitivity datasets and explored the patterns of concordant sensitivity that arise 
within them. The NCI-DTP has evaluated more than 10,000 compounds for evidence 
of the ability to inhibit cancer cell growth using a sulforhodamine B (SRB) assay in 
60 human tumor cell lines. Oncotest has investigated the inhibition of anchorage 
independent growth activity of over 100 anticancer agents using an in vitro Tumor 
Clonogenic Assay (TCA) in more than 200 tumor explant models. In this study, we 
analyze in vitro NCI’s SRB assay drug sensitivity data in 54 cancer cell lines (we 
exclude leukemia cell lines) and Oncotest’s TCA drug sensitivity data in 52 solid 
tumor explant models on 14 anticancer cytotoxic agents (Table 4-1). The selected 
tumor types in two datasets are similar – both include breast, colon, lung, melanoma, 
ovarian and renal cancers – but none of the individual models appears in both data 
sets. Leukemia cell lines and explant models are excluded in the study as they have 
previously demonstrated elsewhere to show high sensitivity to multiple agents in 
NCI60 data[197], whereas other tumor types are seen to show divergent response to 
multiple agents in both datasets. 
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Doxorubicin Cytotoxic/antitumor antibiotic 
Mitoxantrone Cytotoxic/antitumor antibiotic 
Docetaxel Spindle poisons/mitotic inhibitors 
Paclitaxel Spindle poisons/mitotic inhibitors 
Vinblastine Spindle poisons/mitotic inhibitors 
Vincristine Spindle poisons/mitotic inhibitors 
Etoposide Topoisomerase inhibitors 
Irinotecan Topoisomerase inhibitors 
Topotecan Topoisomerase inhibitors 
Table 4-1: 5 types of standard of care chemotherapy agents included in the study are: 
alkylating/alkylating-like(3), antimetabolites(2), antitumor antibiotic(2), spindle 
poison/mitotic inhibitor(4) and topoisomerase inhibitor(3) 
In order to identify the pattern of in vitro chemo-response for 14 anticancer 
cytotoxic agents, we classified the samples into three classes for each agent: Sensitive, 
Medium and Resistant. The chemo-response data (GI50 and IC50) is negatively 
log-transformed (NLog) and discretized into three levels using an agglomerative 
clustering method. This “discretization level coalescence” method incrementally bins 
the number of discretization levels for the chemo-response data of each agent while 
minimizing the loss of total mutual information between the agents[198]. In this case, 
only 5% of mutual information was lost. We then define a Concordance Rate to 
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represent the concordance of chemotherapeutics within a class for each sample across 
all 14 cytotoxic agents. The Concordance Rate (Sensitive) is defined as: 
 
 












Similarly, we define Concordance Rates for the Medium and Resistant classes.  
We next performed the analysis of estimated concordance rate for both 
NCT-DTP and Oncotest drug sensitivity data in the selected anticancer cytotoxic 
agents. The analysis of concordance rates based on 54 NCI human cell lines for 14 
cytotoxic agents reveals that 8/54(15%) of cell lines show a Concordance 
Rate(Sensitive) of 67% or higher, including 1 breast (MCF7), 1 CNS (SF_539), 1 
colon (HCT116), 2 melanoma (LOXIMVI, UACC_62), 1 non-small cell lung cancer 
(NCH_H460) and 1 prostate (DU_145). 7/54 (13%) of cell lines show a Concordance 
Rate(Resistant) of 67% or higher, including include 1 melanoma (SK_MEL_2), 2 
non-small cell lung cancer (NCI_H322M, EKVX), 2 ovarian ( OVCAR_4, 
OVCAR_5) and 2 renal (UO_31, TK_10). The difference of NLogGI50 between 
concordant sensitive samples and concordant resistant samples represent more than 
10-fold differences in sensitivity. For example, the median of NLogGI50s of 
concordant sensitive cell line NCI_H460 among 14 cytotoxic agents is 8.07, while the 
median of NLogGI50s of concordant resistant cell line TK_10 is only 5.89. 
The analysis of concordance rates based on 52 Oncotest explant models in 
TCA for 14 cytotoxic agents shows that 8/52(15%) samples with a Concordance Rate 
(Sensitive) of 67% or higher, including 1 breast (MAXF_401), 1 multiple myeloma 
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(MMXF_L363), 3 non-small cell lung cancer (LXFL_1121, LXFA_983, 
LXFE_1422), 1 prostate (PRXF_22RV1LX), 1 bladder (BXF_1218) and 1 uterine 
(UXF_1138LX). 8/52 (15%) samples show a Concordance Rate (Resistant) of 67% or 
higher, including 1 colon (CXF_975), 3 non-small cell lung cancer (LXFA_289, 
LXFA_1041, LXFA_297), 3 ovarian (OVXF_899, OVXF_550, OVXF_1023) and 1 
renal (RXF_423). The most sensitive sample, UXF_1138LX, shows a median 
NLogIC50 of 8, which is almost 1,000 fold over the most resistant sample LXFA_289 
with a median NLogIC50 of only 5. Figure 4-1 and Figure 4-2 depict the normalized 
chemo-response data of NCI-DTP and Oncotest respectively with the concordant 
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Table 4-2: Summary of concordant sensitive and concordant resistant cell 
lines/explants in NCI60 and Oncotest for 14 anticancer agents. 15 NCI-DTP cell lines 










MCF7 Breast 100 LXFL_1121 Lung 85 Sensitive 
SF_539 CNS 86 LXFA_983 Lung 82 Sensitive 
HCT_116 Colon 71 BXF_1218 Bladder 79 Sensitive 
LOXIMVI Melanoma 93 LXFE_1422 Lung 77 Sensitive 
UACC_62 Melanoma 78 UXF_1138LX Uterine 77 Sensitive 
NCI_H460 Lung 93 PRXF_22RV1LX Prostate 71 Sensitive 
DU_145 Prostate 92 MAXF_401 Breast 67 Sensitive 
X786_0 Renal 69 MMXF_L363 Multi-Myeloma 67 Sensitive 
SK_MEL_2 Melanoma 71 LXFA_289 Lung 67 Resistant 
NCI_H322M Lung 71 RXF_423 Renal 71 Resistant 
EKVX Lung 93 OVXF_899 Ovarian 73 Resistant 
OVCAR_5 Ovarian 71 OVXF_550 Ovarian 73 Resistant 
OVCAR_4 Ovarian 71 LXFA_1041 Lung 75 Resistant 
UO_31 Renal 71 LXFA_297 Lung 75 Resistant 
TK_10 Renal 93 CXF_975 Colon 82 Resistant 
   OVXF_1023 Ovarian 92 Resistant 




red: positive, white: zero, blue: negative 
Figure 4-1: Concordant chemotherapeutics is observed in NCI-DTP 60 cell lines’ 
screening data in SRB assay for 14 cytotoxic agents 




red: positive, white: zero, blue: negative 
Figure 4-2: Concordant chemo-sensitivity is observed in Oncotest explants’ screening 
data in TCA for 14 cytotoxic agents 
4.2.2 A novel gene expression signature to characterize concordance 
of chemotherapeutics 
From the NCI-DTP drug sensitivity data, we used the 15 cell lines with ≥67% 
Concordance Rate (8 Sensitive + 7 Resistant) as evidence for high concordance 
among chemotherapeutics, and explore to see if there was any molecular distinction 
between them that is visible in genomic expression data. We tagged these 15 cell lines 
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as members of a “CS” (concordant sensitive) group and a “CR” (concordant resistant) 
group, respectively. Differential gene expression analysis (see methods and materials) 
was then employed to develop a gene signature to characterize the concordant 
groupings as a phenotype, predicted using basal gene expression profiles available 
from GEO (GSEA5720)[199]. The gene signature consists of 168 genes (176 
probesets) that are significantly differentially expressed between concordant sensitive 
samples and concordant resistant samples (Figure 4-3, Appendix-1). Using a 
metagene method with a Bayesian binary regression procedure (see materials and 
methods), each sample is assigned a probability of sensitivity (POS) between 0 and 1 
by the signature predictor. A box plot of the probability of sensitivity clearly shows 
the pattern of concordant sensitivity and concordant resistance among 15 samples 
(Figure 4-4).  




Figure 4-3: Heatmap of gene expression signature of concordant chemotherapeutics 
(red: high, white: medium, blue: low) 




yellow: concordant sensitive cell lines; blue: concordant resistant cell lines 
Figure 4-4: Boxplot of in-sample predicted (fitted) probability of sensitivity of the 
gene signature predictor of concordant chemotherapeutics in 15 NCI60 cell lines  
4.23 Independent validation in Oncotest explants models 
Subsequently, we then tested to assess if the signature predictor of 168 genes 
differentially expressed in concordant sensitive versus concordant resistant cell lines 
can predict concordant chemo-response in tumor derived explants from the Oncotest 
data. The hypothesis is that if the expression pattern of the signature genes remains 
significantly intact and non-random, then the signature predictor will be able to 
predict the concordance of chemotherapeutics for multiple cytotoxic anticancer agents 
in both cell lines and tumor model derived explants. Using the basal gene expression 
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data generated by Oncotest, we applied the predictor to 16 explants tumor models that 
include 8 concordant sensitive explants and 8 concordant resistant explants. The 
predicted probability of sensitivity (POS) of 16 explants tumor models is shown in 
Figure 4-5. The performance of the predictor is AUC=0.88±0.10 (Figure 4-6), which 
is significantly greater than 0.5 and suggests that the signature predictor is 
non-random. Figure 4-7 depicts the ECDF plot, which shows the robustness of the 
specified POS cutoff. For example, when the cutoff of POS moved from 0.35 to 0.94, 
6/8 (75%) concordant sensitive explants models(symbol:: triangle) and 8/8 (100%) 
concordant resistant explants models (symbol:: plus) were identified. This broad 
cutoff of probability of sensitivity (POS) also maximizes the sum of true positive rate 
and true negative rate. Therefore, the performance of the signature predictor of 
concordant chemotherapeutics in the independent in vitro validation using the 
Oncotest explant materials suggests that the genomic signature is valid and robust for 
pre-clinical solid tumor models of human tumors.  
 




Figure 4-5: Boxplot of predicted probability of sensitivity of applying the gene 
signature predictor of concordant chemotherapeutics in 16 Oncotest explants models 
 




Figure 4-6:  Receiver Operating Characteristic (ROC) curves of applying the gene 
signature predictor of concordant chemotherapeutics in 16 Oncotest explants models 
 




X-Axis: probability of sensitivity (POS), Y-Axis: the fraction of samples for POS is less than 
the cut-off value 
Figure 4-7: Empirical cumulative distribution of predicted probability of sensitivity 
(POS) of applying gene signature predictor of concordant chemotherapeutics in 16 
Oncotest explants models 
4.2.4 Independent validation in clinical patients treated with (TFAC) 
combination chemotherapy 
To assess whether the signature of concordance was detectable in patient 
tumor samples and had potential clinical utility, we investigated whether the signature 
was able to show predictive ability for combination chemotherapy from published 
studies. Microarray expression data was used from a clinical cohort of 133 breast 
cancer patients undergoing neoadjuvant treatment with the TFAC (paclitaxel, 
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5-fluorouracil, adriamycin, and cyclophosphamide) chemotherapy regimen[200]. To 
further dissect the general resistance TFAC chemotherapeutics, we apply our gene 
signature predictor of concordant chemotherapeutics to this breast cancer datasets of 
(126) tumor samples with clinical treatment results available (32 pathological 
complete response (pCR) and 94 residual invasive cancer (RD) responses. To follow 
standard quality control practices for clinical microarray data[201-203], we 
preprocess the microarray data for quality standards by removing low expression, low 
variation and poor quality gene level annotated probesets. The original 168-gene 
signature is therefore reduced to a signature of 23 genes (25 probsesets) in this 
particular breast cancer dataset. The performance of the signature predictor is 
AUC=0.63±0.06 (Figure 4-8). Although the AUC value is not very high compare with 
the performance in Oncotest explants data, “p-value=0.017” clearly demonstrates that 
the signature predictor is significantly non-randomly present in TFAC treated breast 
cancer patients. Hence, we can conclude that the developed gene expression signature 
of concordant chemotherapeutics is a robust signature and it is translatable across 
tumor types and clinical patients. 




Figure 4-8:  Receiver Operating Characteristic (ROC) curves of applying the 
concordant chemotherapeutics gene signature predictor in 126 breast cancer data with 
patients treated by (TFAC) combinational chemotherapy 
4.2.5 Prediction of clinical outcome in cancer patients 
We next examined the ability of the signature predictor of concordant 
chemotherapeutics to predict clinical outcome in the clinical datasets: Miller 
breast[204] and Bild lung cancer data sets[141]. The patients’ samples are stratified 
into three groups based on predicted probability of sensitivity of concordant 
chemotherapeutics: the samples with top 1/3s highest predicted probability of 
sensitivity of concordant chemotherapeutics are classified as “predicted CS 
(concordant sensitive)” group; and the samples with the lowest 1/3s of predicted 
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probability of sensitivity of concordant chemotherapeutics are classified as the 
“predicted CR (concordant resistant)” group; and the rest of the samples with medium 
predicted probability of sensitivity of concordant chemotherapeutics are classified as 
the “predicted medium” response or “divergent” response group. The Kaplan-Meier 
survival analysis is then performed for the two stratified patients “predicted CS” and 
“predicted CR” groups. Figure 4-9 shows the Kaplan–Meier survival curves for the 
156 breast cancer patients. The predicted CS group patients show much better 
survival than predicted CR group patients with the log-rank test p-value=0.025. 
Figure 4-10 depicts the survival analysis for 74 lung cancer patients. The predicted CS 
group patients show significantly better survival than predicted CR group patients. 
These indicate that the presence of gene signature of concordant chemotherapeutics in 
both breast cancer and lung cancer patients. In clinic, the platins and taxanes are the 
two important standards of care cytotoxic agents, and they are widely used for the 
treatment of breast cancer and lung cancer patients. The strong association between 
the clinical outcome of stratified breast cancer and lung cancer patients by the 
signature of concordant chemotherapeutics signify that the gene signature predictor of 
concordant chemotherapeutics may be potentially useful for tailored chemotherapies 
in clinic for solid tumors. 




Predicted CS: predicted “concordant sensitive” group; predicted CR: predicted “concordant 
resistant” group; P-Value: Log-Rank test probability (null hypothesis: two groups have no 
difference) 
Figure 4-9:  Kaplan–Meier survival curves of stratified predicted “Concordant 
Sensitive” and predicted “Concordant Resistant” breast cancer patients by the gene 
expression signature predictor of concordant chemotherapeutics. The 78 predicted CS 
patients showed a significantly longer disease-free survival time than the 78 predicted 
CR patients (P-Value<0.05). 




Predicted CS: predicted “concordant sensitive” group; predicted CR: predicted “concordant 
resistant” group; P-Value: Log-Rank test probability (null hypothesis: two groups have no 
difference) 
Figure 4-10: Kaplan–Meier survival curves of stratified predicted 
“Concordant Sensitive” and predicted “Concordant Resistant” lung cancer patients by 
the gene expression signature predictor of concordant chemotherapeutics. The 37 
predicted CS patients showed a significantly longer disease-free survival time than the 
37 predicted CR patients (P-Value<0.05).  
4.2.6 Meta-analysis for correlations with other drug sensitivity 
signatures and mechanism study of sensitivity 
Since the concordance signature is proposed to represent concordance among 
multiple anticancer agents excluding the selected 14 agents, we investigated if the 
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signature genes for concordant sensitivity are correlated with sensitivities to other 
anticancer agents using Oncomine database analysis tools[205, 206]. We built two 
signature concepts in the Oncomine system: signature concept-a) 75 genes that are 
over expressed in concordant sensitive samples; signature concept-b) 93 genes that 
are under expressed in concordant sensitive samples. Interestingly, concept a) is only 
significantly associated with 17 signature concepts (Table 4-3), that include 5 unique 
drug sensitivity concepts (3 over expression, 2 under expression). However, concept b) 
is significantly associated with 109 signature concepts (Table 4-4), which include 33 
unique drug sensitivity concepts (5 over expression, 28 under expression). 
Furthermore, the under-expression genes in the proposed signature are highly 
enriched in many other drug sensitivity concepts including Amsacrine, Floxuridine, 
Methodtrexate, Teniposide, Topotecan, Tremetrexate, Cytarabine and Temsirolimus 
“sensitive multi-cancer cell lines concepts” (Figure 4-11), that means the signature 
concept formed by under-expression genes of concordant chemotherapeutics is able to 
predict the chemo-response of other anticancer agents. For example, Figure 4-12 and 
Figure 4-13 describe the signature concept-b) formed by under-expressed genes 
shows consistent expression patterns in Amsacrine and Temsirolimus sensitive cell 
lines respectively. The NCI-DTP drug sensitivity data of Amscrine and Temsirolimus 
also shows apparent sensitive and resistant patterns in 15 concordant sensitive and 
concordant resistant cell lines (Figure 4-14 and Figure 4-15). 
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Threshold: odds ratio=2, p-value=1.0e-4, Red: over-expression, Blue: under-expression 
Table 4-3: The associated concept summary for 75 over-expressed signature genes in 
concordant sensitive cell lines. Image is from OncomineTM. 
 
 
Threshold: odds ratio=2, p-value=1.0e-4, Red: over-expression, Blue: under-expression 
Table 4-4: The associated concept summary for 93 under-expressed signature genes 
in concordant sensitive cell lines. Image is from OncomineTM. 
 




P: My Concepts: under-expressed signature genes of concordant chemotherapeutics 
1. Amsacrine Sensitive - Top 1% Under-expressed (Compendia CellLine) 
2. Floxuridine Sensitive - Top 10% Under-expressed (Compendia CellLine) 
3. Methotrexate Sensitive - Top 10% Under-expressed (Compendia CellLine) 
4. Teniposide Sensitive - Top 1% Under-expressed (Compendia CellLine) 
5. Topotecan Sensitive - Top 5% Under-expressed (Compendia CellLine) 
6. Trimetrexate Sensitive - Top 10% Under-expressed (Compendia CellLine) 
7. Mitomycin C Sensitive - Top 1% Under-expressed (Compendia CellLine) 
8. Foretinib Sensitive - Top 10% Under-expressed (Wooster CellLine) 
9. Cytarabine Sensitive - Top 5% Under-expressed (Compendia CellLine) 
10. Temsirolimus Sensitive - Top 10% Under-expressed (Wooster CellLine) 
11. Doxorubicin Sensitive - Top 10% Under-expressed (Compendia CellLine) 
12. Mitoxantrone Sensitive - Top 10% Under-expressed (Compendia CellLine) 
13. Pazopanib Sensitive - Top 5% Under-expressed (Wooster CellLine) 
14. Bleomycin Sensitive - Top 10% Under-expressed (Compendia CellLine) 
15. Fluorouracil Sensitive - Top 5% Under-expressed (Compendia CellLine) 
16. GSK1070916 Sensitive - Top 10% Under-expressed (Wooster CellLine) 
17. GSK1904529 Sensitive - Top 10% Under-expressed (Wooster CellLine) 
18. SN-38 Sensitive - Top 10% Under-expressed (Gemma CellLine) 
19. Dihydro-5-Azacytidine Sensitive - Top 10% Under-expressed (Compendia CellLine) 
20. Ormaplatin Sensitive - Top 10% Under-expressed (Compendia CellLine) 
21. BEZ235 Sensitive - Top 10% Under-expressed (Wooster CellLine) 
22. Mercaptopurine Sensitive - Top 10% Under-expressed (Compendia CellLine) 
23. Bleomycin Sensitive - Top 10% Under-expressed (Compendia Melanoma CellLine) 
24. Mechlorethamine Sensitive - Top 5% Under-expressed (Compendia CellLine) 
25. Thioguanine Sensitive - Top 5% Under-expressed (Compendia CellLine) 
26. SN-38 Sensitive - Top 10% Under-expressed (Shimokuni CellLine 2) 
27. Paclitaxel Sensitive - Top 10% Under-expressed (Compendia CellLine) 
28. GSK1070916 Sensitive - Top 10% Under-expressed (Wooster Liver CellLine) 
Figure 4-11: Comparison of shared genes across 29 gene signature concepts (under 
expression genes in concordant sensitive cell lines and 28 Oncomine 
chemo-sensitivity signature concepts). Figure is from OncomineTM. 
 






Figure 4-12: Signature concept of under expressed signature genes (20) in Compedia 





Figure 4-13: Signature concept of under expressed signature genes (20) in Wooster 
cell lines show consistent expression pattern as Temsirolimus in vitro drug sensitivity 
profile (OncomineTM). 
Amsacrine Resistant Amsacrine Sensitive 
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Figure 4-14: NLogG50 of Amsacrine for 14 cell lines which show concordant 
chemotherapeutics in NCI60. 6/7 concordant sensitive cell lines show sensitive to 







































































Figure 4-15: NLogG50 of Temsirolimus for 14 cell lines which show concordant 
chemotherapeutics in NCI60. 6/7 concordant sensitive cell lines show sensitive to 
Temsirolimus and 4/7 concordant resistant cell lines show resistant to Temsirolimus. 
Concordant Sensitive Concordant Resistant 
Concordant Sensitive Concordant Resistant 









































































Figure 4-16: NLogG50 of Ridaforolimus for 15 cell lines show concordant 
chemotherapeutics in NCI60. 8/8 concordant sensitive cell lines show sensitive to 
Ridaforolimus and 4/7 concordant resistant cell lines show resistant to Ridaforolimus. 
Cell Lines  Classes  KRas  BRaf  PIK3CA  PTen  STK11 
MCF7  Concordant Sensitive  WT  WT  E545K  WT  WT 
SF_539  Concordant Sensitive  WT  WT  WT  HD  WT 
HCT_116  Concordant Sensitive  G13D  WT  H1047R  WT  WT 
LOXIMVI  Concordant Sensitive  WT  V600E  WT  WT  WT 
UACC_62  Concordant Sensitive  WT  V600E  WT  P248fs*5  WT 
NCI_H460  Concordant Sensitive  Q61H  WT  E545K  WT  p.Q37* 
DU_145  Concordant Sensitive  WT  WT  WT  WT  p.K178fs*86 
786_0  Concordant Sensitive  WT  WT  WT  Q149*  WT 
SK_MEL_2  Concordant Resistant  WT  WT  WT  WT  WT 
NCI_H322M  Concordant Resistant  WT  WT  WT  WT  WT 
EKVX  Concordant Resistant  WT  WT  WT  WT  WT 
OVCAR_5  Concordant Resistant  G12V  WT  WT  WT  WT 
OVCAR_4  Concordant Resistant  WT  WT  WT  WT  WT 
UO_31  Concordant Resistant  WT  WT  WT  WT  WT 
TK_10  Concordant Resistant  WT  WT  WT  WT  WT 
WT: wild type; HD: homozygous deletion; fs: frame shift; *: deletion or substitution. 
Table 4-5: Listed are the mutations of oncogene and tumor suppressor genes in 
mTOR upstream pathways. The mutation data is from COSMIC database.  
Concordant Sensitive Concordant Resistant 
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The topoisomerase-II specific inhibitor Amsacrine belongs to the cytotoxic 
class of topoisomerase inhibitors that include Etoposide, Irinotecan and Topotecan, 
that are included in the 14 agents used in signature development. The strong 
association between signature genes and Amsacrine chemo-sensitivity further 
confirms the predicted ability of the signature of concordant chemotherapeutics as a 
chemo-response predictor to standard of care cytotoxic agents.  
The signature genes are also observed to be significantly correlated with the 
chemo-sensitivity of the kinase inhibitor Temsirolimus (CCI-779) in the Oncomine 
database. Temsirolimus specifically inhibits mTOR and results in growth arrest of 
cells in the G1 phase of the cell cycle. mTOR is a serine/threonine protein kinase that 
integrates the signals of multiple upstream signaling pathways, e.g. IGF, EGF and 
mitogens[207, 208]. The mTOR activity plays a central role in the control of cell 
proliferation, survival, mobility and angiogenesis in multiple solid tumors. To follow 
up on this observation for Temsirolimus, we examined the drug sensitivity of another 
mTOR inhibitor, Ridaforolimus, for which NCI60 data is available. Ridaforolimus 
behaves similarly to Temsirolimus in those NCI60 cell lines (Figure 4-16) with high 
chemotherapeutic concordance. The presence of the signature of concordant 
chemotherapeutics in both Temsirolimus and Ridaforolimus sensitive cell lines may 
indicate that the integrated signal of upstream pathways of mTOR, like Ras/MAPK, 
AMPK and PI3K/Akt is high in concordant sensitive cell lines. As a preliminary 
evaluation of the activity of signaling pathways upstream of mTOR, we tabulated the 
known mutations of 5 cancer genes in mTOR upstream pathways from COSMIC 
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databases (Table 4-5). Based on the mutation information of KRas, BRaf, PI3KCA, 
PTen and STK11, it is evident that each of 8 concordant sensitive cell lines harbors 
known mutations in at least one pathway. However, only 1 of 7 concordant resistant 
cell lines, OVCAR_5, contains 1 of these mutations (KRas G12V). Although the 
activity of mTOR pathway in these cell lines awaits further experimental validation, 
the upstream pathways’ information could provide an indicator that mTOR integrates 
multiple signals to regulate cell proliferations. As a consequence of one or more than 
one active upstream pathway(s), mTOR is active, and cells may proliferate very fast. 
We then analyzed the cell growth rate of NCI60 cell lines. Figure 4-17 depicts the 
doubling time of identified 15 cell lines with high concordance of chemotherapeutics: 
the doubling time of 8 concordant sensitive cell lines is 23.9±6.9 hours and the 
doubling time of 7 concordant resistant cell lines is 43.6±5.2 hours. Apparently, the 
concordant sensitive cell lines grow significantly faster than the concordant resistant 
cell lines. Some other cell lines in NCI60, like SW620 and COLO205 harbor KRas or 
BRaf mutation, and both grow fast in culture medium, but they show very divergent 
chemo-response to multiple cytotoxic agents. The active proliferation pathway is 
maybe one of the critical prerequisites for cells to show sensitive to multiple agents.  
Hence, we hypothesize that solid tumor cells that are sensitive to multiple 
cytotoxic anticancer agents are growing fast with active proliferation pathway(s). We 
estimated the tumor doubling time in the mice of 15 Oncotest tumor models which are 
identified to show concordant chemotherapeutics. As shown in Figure 4-18, 6/8 
concordant resistant explants with tumor doubling time in mice is equal to or more 
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than 8 days, which is much longer than the maximum tumor doubling time in mice of 
7 concordant sensitive explants, at just 5 days.  
As 93 signature genes under-expressed in concordant sensitive samples are 
shown to be significantly associated with multiple drug sensitivity signatures, we then 
performed the enrichment analysis of these genes to assess the overall functional 
implications of the signature of concordant chemotherapeutics and to generate 
additional evidence decoding the biological mechanisms of concordant 
chemotherapeutics. The enrichment analysis was done using MetaCoreTM by GeneGo 
to identify biological functions significantly associated with concordant 
chemotherapeutics. The histogram (Figure 4-19) shows the top 10 enriched GeneGo 
pathway maps for the signature genes under-expressed in concordant sensitive cell 
lines. The protein signaling pathways, such as notch, WNT, late endocytic and SCF 
are related to the sensitivity of chemotherapeutics. This gives us a clue that the 
concordant resistance in chemotherapeutics is very complicated, and it is a 
combination of multiple biological processes instead of being exclusively driven by a 
single biological pathway. 
 























































































Figure 4-17: The doubling time of 15 NCI60 cell lines identified as high concordance 
of chemotherapeutics. The concordant sensitive cell lines have much shorter doubling 
time than concordant resistant cell lines. 
  
 
Figure 4-18: The tumor doubling time of 15 Oncotest explants models identified as 
high concordance of chemotherapeutics. 
Concordant Sensitive Concordant Resistant 
Concordant Sensitive Concordant Resistant 




Figure 4-19: The top 10 most significantly enriched GeneGo pathway maps for the 
under expressed (in concordant sensitive cell lines) signature genes. The bars 
represent significance as –log(p-value) for hypergeometric distribution. All ontology 
enrichments were filtered at significance level 0.05 (pValue: the significance of the 
enrich biological process) 
4.3 Discussions 
While advances in understanding of cancer genetics, increased use of targeted 
agents, and genetic predictors of response to individual agents have all helped build 
confidence in the promise of personalized medicine, the practical implications are still 
limited: cancer patients are often treated with combinations of multiple agents 
including cytotoxic chemotherapies, whose success in combination cannot be 
predicted in advance for individual patients. A variety of translational strategies using 
preclinical drug sensitivity data and integrative genomics have been proposed to 
address this challenge, including an ever widening range of preclinical models across 
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or within tumor types [209-213]. In addition, systems-based approaches have also 
begun to be applied to combination treatments explicitly, through pathway models 
and other systems approaches still in early stages of development [119, 122, 
214-216]. 
We utilize data from two very different sets of preclinical models – 
immortalized cell lines assayed for cell growth, and patient derived human tumor 
xenograft samples grown in 3D culture and assayed for clonogenic potential – to 
develop independently validated and translationally relevant predictive models of 
drug sensitivity. When tested across the diverse background provided by wide ranging 
models of solid tumors, the data can be used to identify subsets of cell lines and 
patient derived xenografts that show concordant sensitivity or resistance to a range of 
widely used chemotherapeutic agents.  
This concordant chemo-response defined in cell lines has a genomic basis, as 
indicated by the independent predictive power of a signature of concordant response 
in entirely different experimental model settings. The signature is further validated by 
prediction of both response and clinical outcome in clinical genomic data sets from 
patients with different diseases and different treatments. Importantly, genes from the 
signature of concordant response, when used in a meta-analysis of public gene set 
categories or “concepts”, specifically identify multiple gene sets of sensitivity for 
chemotherapeutic agents not in the original training set, consistent with a signature for 
broad chemotherapeutic concordance.  
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The signature is associated with, but not fully explained by, several common 
themes in cancer biology. While related to different proliferation rates in concordant 
sensitive versus concordant resistant models, the signature is a simple consequence of 
differential proliferation, as non-concordant models provide many counter-examples 
along with their divergent sensitivity profiles. The identification of the mTOR 
inhibitor Temsirolimus among agents picked up by the meta-analysis of expression 
signatures is consistent with known genetic activation upstream of mTOR in 
concordant resistant samples, and further supported by analysis of NCI60 sensitivity 
data for the mTOR inhibitor Ridaforolimus, but we do not have experimental mTOR 
pathway data for these cell lines. 
Since most cytotoxic agents interfere with cell cycle processes, it is no 
surprise that these agents are most effective on rapidly growing tumors. The tumor 
proliferative activity and response to first-line chemotherapy (anthracycline, 
clophosphamide, methotrexate and 5-fluorouracil) in advanced breast carcinoma has 
been studied elsewhere [217]. The results show a high response rate (48%) in the 
group with highly proliferative tumors when compared with a response rate of 21% in 
the group with less proliferative tumors. However, regardless of the difference in 
response rate, survival analysis showed no significant difference between the two 
groups based on proliferation rate alone. 
One response to our finding of concordant chemo-response might be for 
researchers designing future studies to remove concordant sensitive and concordant 
resistant cell lines from any training or test set for sensitivity to any agent, on the 
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grounds that including them would reduce the power of a predictive model. This 
approach may be warranted within panels of cell lines or primary models used to 
develop genomic predictors of non-targeted agents. But for either individual cell line 
study or for developing predictive models for targeted agents, we believe this is a 
bridge too far: models from the NCI60 panel showing concordant chemo-response 
have played important roles in cancer biology, and for targeted agents the details of 
these well-characterized models can make them particularly appropriate for target 
hypothesis-based experimentation.  
If the signature of concordance is validated in further patient studies, there 
may be clinical value in identifying patients whose tumors show a signature of 
concordant resistance to chemotherapeutics, to ascertain whether these patients should 
be prioritized for earlier combinations with targeted agents, rather than front-line 
treatment with chemotherapeutic combinations.  
We conclude that the developed gene expression signature could characterize 
the concordance of chemotherapeutics of standard of care agents, and it potentially 
may be applied as the predictor to tailor the patient’s response, given by standard of 
care chemotherapeutics with or without combination in a range of solid tumors. 
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4.4 Methods and Materials 
4.4.1 Anticancer Cytotoxic agents 
The selected 14 Standard of Care (SOC) anticancer cytotoxic agents include 5 
types of inhibitors: alkylating/alkylating-like, antimetabolites, antitumor antibiotic, 
spindle poison/mitotic inhibitor and topoisomerase inhibitor (Table 4-1).  
4.4.2 In vitro tumor explants screening at Oncotest 
The drug sensitivity of 14 anticancer cytotoxic agents were studied by Tumor 
Clonogenic Assay (TCA) in Oncotest. TCA studied the inhibition of anchorage 
independent growth and in vitro colony formation of tumor cells derived from human 
tumor xenografts of various tumor histologies in semi-solid medium. The assay is 
performed in a 24-well format with six replicates for untreated controls and three 
replicates for treatment wells. Agent effects are expressed in terms of the percentage 
of colony formation, obtained by comparison of the mean number of colonies in the 
treated wells with the mean colony count of the untreated controls (relative colony 
count expressed by the mean of treatment versus mean of control) [7]. IC50 is the 
drug concentrations necessary to inhibit colony formation by 50% (Treatment 
/Control = 50%). Four parameter dose response curves to determine these 
concentrations are fit. If an IC50 value could not be determined within the examined 
dose range because an agent was either too active or lacked activity, the lowest or 
highest concentration studied was used for the calculation.  
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4.4.3 In vitro cell line screening at NCI-DTP 
The National Cancer Institute (NCI) Developmental Therapeutics Program 
(DTP) program, cell lines and assay related details are given at http://dtnci.nih.gov/. 
The 14 cytotoxic agents’ chemo-response profile in NCI was reported in the DTP 
database. The database provides the estimates of concentration for IC50 (the 
concentration that cause 50% cells inhibition 100 × T/C = 50), GI50 (the 
concentration of test drug where 100 × (T - T0)/(C - T0) = 50, T0 is the optical 
density (response) of the “test well” at time zero), TGI (the concentration of test drug 
where 100 × (T - T0)/(C - T0) = 0, it signifies cytostatic effect) and LC50 (the 
concentration of drug where 100 × (T - T0)/T0 = -50), which are defined at 
http://dtnci.nih.gov/branches/btb/ivclshtml. 
4.4.4 Microarray data 
The tumor sample with TCA data were prepared by Oncotest and the 
microarray data was generated at Microarray Facility, Medical Genetics, Tuebingen, 
Germany (http://www.microarray-facility.com) as per the guidelines for Affymetrix 
gene expression microarrays (Affymetrix Inc., Santa Clara, USA). The expression 
profiling used RNA is from explant materials that were derived primary tumors. 
Following the sacrifice of mice by cervical dislocation, tumors of 400-600 mm^3 
volume were excised without delay, and tumor pieces free of necrosis were flash 
frozen in liquid nitrogen. For gene expression profiling of human tumor xenografts, 
total RNA was purified using the RNeasy Mini kit (QIAGEN, Hilden, Germany). 
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During RNA isolation, no genomic DNA digestion was done. Prior to hybridizing to 
microarrays, 1.2 µg of total RNA was amplified using the One-Cycle Eukaryotic 
Target Labeling Assay (Affymetrix Inc., Santa Clara, USA). 15 µg of labeled 
complementary RNA (cRNA) was then hybridized to Affymetrix HG-U133 Plus 2.0 
GeneChip expression array. The CEL files were processed using a statistical package 
R-project environment version 2.12.0 (http://www.r-project.com) with Bioconductor 
package version 2.7. The signal for probesets were condensed using MAS5.0 
algorithm, normalized to 500 fluorescence units, followed by log base 2 
transformation. The publicly available microarray datasets were downloaded from 
NCBI. Breast cancer (Hess et al. 2006) dataset (Affymetrix U133A gene expression 
array) was downloaded from http://www.bioinformatics.mdanderson.org 
/pubdata.html. NCI60 cell line expression dataset (Affymetrix U133A and U133B 
gene expression array) is available as accession number GSE5720 at NCBI's Gene 
expression omnibus. Bild lung [141] cancer and Miller breast [204] datasets 
(Affymetrix U133 plus2 gene expression array) are available as accession number 
GSE3141 and GSE3494 respectively at NCBI's Gene expression omnibus.  
4.4.5 Statistical analysis method 
Gene expression data is filtered to exclude probesets that show background 
level expression and that do not vary significantly across samples. Furthermore, the 
probesets are selected to be significantly differentiated between sensitive and resistant 
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samples using FDR (false discovery rate) criteria. The analysis uses R package 
“limma” (Linear Models for Micorarray Data[105])) (version 3.6.6).  
The statistical method to generate the probability of chemotherapeutic 
sensitivity uses standard binary regression models combined with singular value 
decompositions (SVD) [79]. Here for simplicity, we name it as “Bayesian-SVD” 
method. First, the probeset selection from the training data is done as stated above. 
Training data is constructed with samples in columns and probesets (or genes) in 
rows. Principal components of the training data are used to compute the metagene and 
metasample values. Bayesian binary probit regression model is fitted to the metagene 
signature for assessing the relevance of each metagene and the classes of 
chemo-response of training samples. We assess the performance of the signature in an 
independent test data. Given the test data set, the gene expression data with probesets 
matched with signature is then projected onto the metagenes from the training data. 
The model was fitted and relative probability of sensitivity (POS) is predicted using 
the Bayesian binary probit regression parameters fitted from the metagene signature. 
The classes are defined as ‘0’ for resistant and ‘1’ for sensitive for training such that 
low POS scores would be suggestive of a sample being resistant and vice versa. The 
implementation based on methodology is done in R environment (version 2.5 and 
above).  
We use a Receiver Operating Characteristic (ROC) curve to plot the true 
positive rate (sensitivity) and false positive rate (1-specificity) for different cutoff 
levels of the POS score estimated above. The Area Under Curve (AUC) is a measure 
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of the accuracy of the test. ROC curve and AUC analysis are done using R packages 
PresenceAbsence version 1.1. Empirical Cumulative Distribution Function (ECDF) is 
a cumulative distribution function that assigns probability ‘1/N’ to each of the ‘N’ 
cases in a sample. A cumulative distribution function (CDF) gives the probability 
when a random variable X is less that a given value x. (CDF(x) = Pr{X ≤ x}). An 
ECDF is a sample based estimate of this theoretical function. The ECDF plots are 
generated using R environment’s base package. The Kaplan-Meier survival analysis is 
performed using the Cox-Mantel log-rank test in R “survival” package version 2.36-1. 
The log-rank test p-value represents the significance of the difference of the probably 
of survival between different patient groups. 
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Chapter 5 Conclusions and discussions 
As the dissertation comes to end, it is important to highlight the important 
findings and address a number of remaining issues. Firstly, the systematic 
bioinformatics methodology to develop principle genomic markers introduced in 
chapter 2 and chapter 3 is reviewed. In particular, miRNA expression markers, that 
has been largely ignored, has been highlighted for discussion. Building on this 
discussion, the miRNA expression markers are generated for the concordant 
chemotherapeutics. These interesting results may suggest some concrete direction for 
future research to extend the genomic marker of concordant chemotherapeutics 
presented in chapter 4. The conclusion of the dissertation will focus on the 
contributions of this work to the cancer research society. 
5.1 Discussion of integrated genomic markers development 
The starting point to develop genomic markers for chemotherapeutics is from 
the fuzzy classification of chemo-response data. We use fuzzy data instead of actual 
numeric readout of GI50 and IC50 data because of its inherent variability of the 
readouts from the in vitro assay screening. Classification of “sensitive”, “medium” 
and “resistant” can also relate to the pathological response of the treatment of the 
anticancer agents in clinical patients, which is usually classified as “complete 
response / partial response”, “stable disease” and “progressive disease”. Since the 
chemo-response data is classified into fuzzy classes, correspondingly, the phenotypic 
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expression, like gene expression and protein expression data can be considered as 
“high”, “medium” or “low”. Therefore, we proposed two types of genomic markers:  
type-I and type-II markers. Type-1 markers are significantly correlated with the rank 
of chemo-response classes. Type-II markers are the combination of significantly 
differentiated genes sets between pair-wise chemo-response classes. To move the 
developed the multiple-gene signature biomarker assay into clinical practice is very 
challenging due to poor choice of assay genes and lack substantial preclinical 
validations[218, 219]. The integrated genomic marker analysis is the method to select 
the reliable assay markers and move into further validation, by which, the genomic 
aberrations, such as gene mutation, DNA copy number variations and methylation, are 
incorporated into the analysis to explain high or low expression patterns of the 
specific candidate marker. The marker with its expression significantly affected by the 
genomic aberration(s) may be considered as potential clinical candidate biomarker, 
and is to be followed up with further assay validations.  
5.1.1 MicroRNAs correlated with chemo-response 
However, there are certain limitations in selecting potential clinical candidate 
biomarker from initial multi-gene expression signature using this integrated genomic 
analysis. The gene or protein expression can be modulated from DNA-RNA 
transcription to the post-translational modification for a protein. The genomic 
aberrations considered in this study are only the modification of DNAs. The gene can 
also be post-transcriptionally regulated by microRNAs, that binds to complementary 
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sequences on target messenger RNA transcripts, and usually resulting in translational 
repression and silence of the gene[50, 51]. It is important to include the microRNA 
information in the study to interpret the expression pattern of candidate markers. For 
example, as shown in Figure 5-1, the expression of miRNA-30 family is identified to 
be significantly correlated with the concordant sensitive and concordant resistant cell 
lines categorized in NCI60 data in chapter 4. Although it has been revealed that 
miRNA-30s may target TP53 protein[220], regulate B-Myc activity together with 
miRNA-29[221] and play very critical roles in causing familial breast cancers[222], 
the targets of miRNA-30 family are still ambiguous. It is difficult to interpret the 
biological mechanisms of miRNA-30s when integrating with prior developed gene 
expression biomarkers from the developed gene signature of concordant 
chemotherapeutics. Alternatively, it is believed miRNA-30s should be further 
explored, especially their roles in multiple proteins signaling pathways. 
 




Figure 5-1: The expressions of miRNA-30 family are significantly correlated with 
concordant chemotherapeutics samples 
5.1.2 Trans-modulation 
The karyotype of a chromosomal segment affects its copy number variation. 
The expression of a gene is usually affected by the copy number variations, mutation 
and DNA methylation. The integrated genomic analysis model is proposed in chapter 
3 with the focus on the gene expression and its own mutation, copy number variation 
and DNA methylation. However, the genetic aberrations can also modulate the 
expressions on the other locus. Therefore, the integrated genomic model should 
associate non-local genetic aberrations of chromosomal segment copy number 
variations with the maker’s expression. Yeang presented a multiple-layer modeling 
framework to identify the statistical and putative causal relations of the gene 
expression and non-local genetic aberrations of chromosomal segment copy number 
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variations, mutation and methylation[223] based on known mechanistic links. Based 
on this reference, we can modify the integrated model proposed in chapter 3 as 
follows: 
,,,,, 32221103222110  aaaaaMeaCNVaCNVaMuaay ijiii Eq 5-1 
Here, jCNV  is the mechanistic link which is reported to trans-modulate the 
expression of gene i. If the number of known trans-modulation copy number variation 
is more than 1, j may take a series of numbers. 
As we discussed in the chapter 1, the potential model, Eq 1-2, has incorporated 
eQTL SNP variation information, which may also consider the unknown non-local 
genetic aberrations. Since the objective of the integrated genomic analysis is to 
identify more robust expression makers and move them into clinical validation, the 
proposed model may be more meaningful. Thus the accuracy of our analysis may be 
low if unknown non-local molecular aberrations are shown to be significantly 
associated with the expression of the marker gene. The proposed integrated model can 
be used to explore the possible biological links between the gene expression and 
non-local genetic aberrations. 
5.2 Proteomic expression markers 
In this dissertation, we have focused on the gene expression markers. As we 
introduced in chapter 2, protein expression signature is another type of important 
principle expression markers. While gene expression can now be measured reliably 
and reproducibly in high throughput[202, 203, 224-227], protein expression 
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measurement technologies are still limited at relatively low and medium throughput. 
However, technologies like reverse phase protein arrays (RPPA) and reverse phase 
lysate arrays (RPLA) seems to provide a reliable high throughput platform to utilize 
the proteomic expression data for exploring the potential biomarkers for 
chemotherapeutics[228]. 
Therefore, we developed the protein expression signature to characterize the 
concordant chemotherapeutics. As shown in Figure 5-2, the 30 proteins (antibodies) 
expression signature includes 7 over expressed and 23 under expressed (in concordant 
sensitive cell lines) proteins. Although the expression pattern is not very concrete 
compared to the gene expression signature, this does give us another scope to decode 
the concordant chemotherapeutics. Interestingly, both tumor suppressor genes, TP53 
and RB1 are under-expressed in concordant sensitive cell lines, and these cell lines 
have high proliferation rate than resistant cell lines. Although no critical conclusion is 
drawn from the protein expression signature, it does expand our understanding of the 
activation status of multiple protein networks, and provides a basis for further looking 
into the integration with genomic analysis results such as gene expression signature 
and miRNA markers. 




Figure 5-2: The protein expression signature of concordant chemotherapeutics (red: 
high value; blue: low value). Signature is derived with LogFC=0.6 and FDR=0.2. 
 
5.2 Extension for future work 
One of the most important bioinformatics analyses is to offer one-step 
validations for the experimental scientist. It is my special interest to suggest a few 
biological experiments to further discover novel biology. There are a few important 
and putative hypothesis considered that can be studied experimentally. 
Chapter 5 Conclusions and discussions 
156 
 
The mTOR upstream signaling pathways in concordant sensitive cell lines are 
more active than in concordant resistant cell lines. The phosph-mTRC1 and 
phosph-mTRC2 activity may be measured in the NCI60 concordant sensitive cell 
lines and concordant resistant cell lines. 
Another interesting follow up is that the miRNA-30s family show significantly 
differentiation patterns in concordant sensitive and concordant resistant samples. The 
general understanding that miRNA-30s may play important role in protein signaling 
pathways[229-231] is poor: there is very few published research papers reported to 
date. Our results indicate that it may play a critical role in the pan-resistance of 
chemotherapeutics. 
5.3 Contributions 
In this dissertation, we have made a number of significant contributions to the 
society of biomarker research in two main areas: a) methodologies development: we 
introduced fuzzy classification of biological data, two types of principle expression 
biomarker and the development algorithms, and then an integrated genomic analysis 
method between gene expression and genomic aberrations is proposed to narrow 
down the multiple-gene signature to few(<10) gene markers or find a single gene 
marker; and b) novel biology：  we identified an important phenomena of 
chemotherapeutics - cancer cells may show concordant chemotherapeutics to multiple 
anticancer agents. To understand the underlying biology of concordant 
chemotherapeutics in cancer cells, we first categorized concordant sensitive and 
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concordant resistant cell lines, and primary derived tumor grafts. We then developed 
the gene expression signature of concordant chemotherapeutics using NCI60 data, 
with robust in-vitro validation in Oncotest tumor graft data. Thereafter, we employed 
the signature to predict the TFAC treated breast cancer patients’ samples and to 
stratify patients groups in both breast and lung cancer to evaluate the prognostic value 
of the signature. From the following meta-analysis in Oncomine database, we found 
that the signature genes are highly enriched in multiple signature concepts of 
anticancer agents. Furthermore, the concordant sensitive cell lines and tumor grafts 
are found to have higher proliferation rate than concordant resistant cell lines and 
tumor grafts. The mutational analysis may suggest that multiple protein signaling 
pathways may be hyperactive. Although this putative hypothesis needs to be tested 
experimentally, the developed gene signature of concordant chemotherapeutics is 
valuable, and should be moved into next step, which is validation. 
In order to demonstrate the end-to-end application of the biomarker 
development framework, we introduced a number of meaningful and signature 
concepts with suitable classification concepts for this particular domain. In particular, 
we proposed to use an integrated genomic analysis model to identify clinical like 
biomarkers. In the contribution of novel biology, we demonstrated that the identified 
biological phenomena “concordant chemotherapeutics” is present in both preclinical 
models and clinical patients.  
Finally, we hope that this dissertation helps biomarker scientists better 
understand the biomarker development process, and offers cancer research scientists a 
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Applendix-1: The gene signature genes and probesets (Affymetrix U133 A&B) of the 
concordant chemotherapeutics 
Probesets Gene Symbol 
Expression in 
Sensitive Cell Lines 
logFC 
242541_at ABCA9 Up 1.25 
231299_at AGAP3 Up 1.96 
229709_at ATP1B3 Up 1.66 
229018_at C12orf26 Up 2.03 
219260_s_at C17orf81 Up 1.07 
239208_s_at C21orf57 Up 1.77 
235219_at C5orf55 Up 1.5 
235981_at C8orf22 Up 1.55 
57715_at CALHM2 Up 1.69 
211347_at CDC14B Up 1.77 
206474_at CDK17 Up 1.52 
210689_at CLDN14 Up 1.74 
226751_at CNRIP1 Up 3.23 
220323_at CNTD2 Up 1.3 
205653_at CTSG Up 1.2 
241381_at CXorf36 Up 1.32 
218808_at DALRD3 Up 1.36 
219328_at DDX31 Up 1.65 
207379_at EDIL3 Up 1.85 
240528_s_at EXOC4 Up 1.59 
225099_at FBXO45 Up 1.03 
241671_x_at FLJ22536 Up 1.61 
219170_at FSD1 Up 2.09 
235574_at GBP4 Up 1.52 
220265_at GPR107 Up 1.17 
220042_x_at HIVEP3 Up 1.2 
227361_at HS3ST3B1 Up 2.65 
235301_at KIAA1324L Up 1.82 
228476_at KIAA1407 Up 1.48 
230432_at LOC100422737 Up 1.3 
235494_at LSAMP Up 1.45 
242838_at MAP6D1 Up 1.27 




214270_s_at MAPRE3 Up 2.36 
208595_s_at MBD1 Up 1.39 
201151_s_at MBNL1 Up 1.03 
222867_s_at MED31 Up 1.15 
225316_at MFSD2A Up 1.37 
228592_at MS4A1 Up 1.43 
222570_at NCS1 Up 1.25 
226585_at NEIL2 Up 1.94 
206929_s_at NFIC Up 1.71 
222057_at NOL12 Up 1.76 
209629_s_at NXT2 Up 1.91 
219295_s_at PCOLCE2 Up 1.67 
236135_at PNPLA7 Up 1.73 
207000_s_at PPP3CC Up 1.29 
209599_s_at PRUNE Up 1.44 
205961_s_at PSIP1 Up 1.06 
243777_at RAB7L1 Up 1.26 
226945_at RHBDD1 Up 1.24 
218861_at RNF25 Up 1.57 
210426_x_at RORA Up 1.44 
222559_s_at RPRD1A Up 1.28 
236782_at SAMD3 Up 1.33 
215834_x_at SCARB1 Up 1.66 
211708_s_at SCD Up 2.25 
242064_at SDK2 Up 1.23 
244653_at SETD7 Up 1.61 
210135_s_at SHOX2 Up 2.18 
219713_at SHPK Up 1.33 
210567_s_at SKP2 Up 1.11 
218978_s_at SLC25A37 Up 1.22 
228935_at SLC4A8 Up 1.55 
213854_at SYNGR1 Up 1.46 
210053_at TAF5 Up 1.32 
222053_at TAF6L Up 1.12 
230394_at TCP10L Up 1.39 
223523_at TMEM108 Up 2.21 
223462_at TMEM175 Up 1.28 
213725_x_at XYLT1 Up 1.74 
203604_at ZNF516 Up 1.39 




232137_at ZNF616 Up 1.44 
215767_at ZNF804A Up 2.05 
219488_at A4GALT Down -1.57 
228132_at ABLIM2 Down -1.54 
211712_s_at ANXA9 Down -1.87 
242727_at ARL5B Down -1.04 
212312_at BCL2L1 Down -1.37 
229975_at BMPR1B Down -3.39 
224435_at C10orf58 Down -2.01 
228155_at C10orf58 Down -2.27 
239777_at C14orf182 Down -2.06 
219010_at C1orf106 Down -1.51 
223951_at C21orf116 Down -1.48 
213199_at C2CD3 Down -1.17 
224707_at C5orf32 Down -1.26 
209495_at CEP250 Down -1.18 
204233_s_at CHKA Down -1.63 
204266_s_at CHKA Down -2.15 
222549_at CLDN1 Down -1.89 
224815_at COMMD7 Down -1.01 
201906_s_at CTDSPL Down -1.02 
201905_s_at CTDSPL Down -1.46 
201904_s_at CTDSPL Down -2.81 
202295_s_at CTSH Down -1.37 
214782_at CTTN Down -1.01 
238280_at CYB5RL Down -1.5 
230679_at DCAF10 Down -1.96 
202500_at DNAJB2 Down -1.77 
204720_s_at DNAJC6 Down -1.58 
204947_at E2F1 Down -1.24 
228256_s_at EPB41L4A Down -2.07 
224024_at ERGIC1 Down -1.73 
208297_s_at EVI5 Down -1.21 
223058_at FAM107B Down -1.57 
223059_s_at FAM107B Down -1.6 
223745_at FBXO31 Down -1.62 
217342_x_at FLJ11292 Down -1.22 
202838_at FUCA1 Down -1.73 
208505_s_at FUT2 Down -1.31 




213343_s_at GDPD5 Down -1.91 
242281_at GLUL Down -1.38 
203108_at GPRC5A Down -3.17 
227614_at HKDC1 Down -2.83 
201655_s_at HSPG2 Down -2.31 
216268_s_at JAG1 Down -1.66 
31849_at KRT80 Down -2.68 
12531_at LCN2 Down -2.15 
221115_s_at LENEP Down -1.96 
219181_at LIPG Down -1.38 
230388_s_at LOC644246 Down -1.08 
204682_at LTBP2 Down -1.02 
228885_at MAMDC2 Down -1.48 
235106_at MAML2 Down -1.75 
216206_x_at MAP2K7 Down -1.19 
210136_at MBP Down -2.8 
202616_s_at MECP2 Down -1.32 
244741_s_at MGC9913 Down -2.34 
224685_at MLLT4 Down -1.01 
233539_at NAPEPLD Down -1.29 
218414_s_at NDE1 Down -1.46 
235517_at PACRGL Down -1.8 
207717_s_at PKP2 Down -2.4 
219024_at PLEKHA1 Down -1.28 
202065_s_at PPFIA1 Down -1.07 
202066_at PPFIA1 Down -1.33 
49077_at PPME1 Down -1.05 
217841_s_at PPME1 Down -1.39 
238118_s_at PPOX Down -1.72 
226907_at PPP1R14C Down -1.59 
228494_at PPP1R9A Down -1.31 
238441_at PRKAA2 Down -2.66 
221808_at RAB9A Down -1.11 
219026_s_at RASAL2 Down -1.58 
226436_at RASSF4 Down -1.49 
226164_x_at RIMKLB Down -1.09 
221215_s_at RIPK4 Down -1.68 
228044_at SERP2 Down -1.51 
233753_at SFRS15 Down -1.53 




223698_at SLC25A36 Down -1.37 
242274_x_at SLC25A42 Down -2.02 
244353_s_at SLC2A12 Down -1.33 
228221_at SLC44A3 Down -1.64 
222967_at SLC5A7 Down -2.05 
238691_at SNHG10 Down -1.67 
218705_s_at SNX24 Down -1.27 
213667_at SRCAP Down -2.08 
226932_at SSPN Down -1.99 
226822_at STOX2 Down -1.25 
202565_s_at SVIL Down -1 
235762_at TAS2R14 Down -1.81 
203221_at TLE1 Down -1.09 
203222_s_at TLE1 Down -1.9 
238802_at TYSND1 Down -1.68 
226678_at UNC13D Down -1.74 
204929_s_at VAMP5 Down -2.3 
235023_at VPS13C Down -1.58 
210248_at WNT7A Down -1.88 
213085_s_at WWC1 Down -1.41 
239757_at ZFAND6 Down -1.4 
216710_x_at ZNF287 Down -1.72 
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